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1. INTRODUCTION 
HEALTH 
Health is a level of functional and metabolic efficiency of a living organism. In 
humans, it is a general condition of a person’s mind and body, usually meaning to be free 
from illness, injury or pain. The world health organization defined health in its broader sense 
in 1946 as a state of complete physical, mental and social well being and not merely absence 
of disease or infirmity. Systematic activities to prevent or cure health problems and promote 
good health in humans are undertaken by health care providers.
1, 2 
DOSAGE FORMS 
Dosage forms are essentially pharmaceutical products in the form in which they are 
marketed for use, typically involving a mixture of active drug components and nondrug 
components, along with other non reusable material that may not be considered either 
ingredient or packing. 
Depending upon the method/route of administration, dosage forms come in several 
types. These include many kinds of liquid, solid and semisolid dosage forms.
3
 
ORAL SOLID DOSAGE FORM 
The convenient oral drug delivery has been known for decades as the most widely 
used route of administration among all the routes. It remains the preferred route of 
administration in the discovery and development of new drug candidates. The popularity of 
oral route is attributed to patient acceptance, ease of administration, accurate dosing, and cost 
effective manufacturing methods and generally improved shelf life of the product. 
Oral solid dosage forms such as tablets and capsules have been formulated and 
developed nowadays since they are the most effective routes of administration of a new drug. 
Pharmaceutical products designed for oral delivery and currently available on the prescription 
and over the counter markets are mostly the immediate release type, which are designed for 
immediate release of drug for rapid absorption. Many new generations of pharmaceutical 
products called controlled and sustained release drug delivery systems have also been 
developed. So the combination of both will be very much useful for immediate response and 
for maintaining the duration of action.
3
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TABLETS 
Tablets are solid dosage forms each containing a unit dose of one or more 
medicaments. They are intended for oral administration. Some tablets are swallowed whole 
or after being chewed, some are dissolved or dispersed in water before administration and 
some are retained in the mouth where the active ingredient is liberated. 
             According to Indian pharmacopoeia, pharmaceutical Tablets are usually solids, flat or 
biconvex, unit dosage form, prepared by compressing a drug or mixture of drugs, with or 
without diluents. They vary in shapes like triangular, rectangular etc. and differ greatly in size 
and weight, depending on the amount of medical substances and the intended mode of 
administration. It is the most popular dosage form and 70% of the total medicines are 
dispensed in the form of tablet. They may have lines or break-marks and may bear a symbol 
or other markings. Tablets may be coated or uncoated. They are sufficiently hard to withstand 
handling without crumbling or breaking
.4
 
ADVANTAGES OF TABLET MEDICATION
5
 
 They are the unit dosage form and offer the greatest capabilities of all oral dosage 
forms for the greatest dose precision and least content variability. 
 Low cost among all oral dosage forms. 
 They are the most compact dosage forms. 
 They are the easiest and cheapest to package and ship. 
 Product identification requires no additional processing steps when employing an 
embossed or monogrammed punch face. 
 Provides greatest ease of swallowing with the least tendency for hang up above the 
stomach, especially when coated provided the tablet disintegration is not excessively 
rapid. 
 They lend themselves to certain special release profile products e.g. enteric coated 
delayed release profiles. 
 Easy large scale production than other oral dosage forms. 
 
 They have the best combined properties of chemical, mechanical and microbiological 
stability among all the oral dosage forms. 
 The emergency supplies of the drug can be conveniently carried by the patient. 
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DISADVANTAGES
5
 
 Some drugs have resistance for compression into dense compacts, owing to their 
amorphous nature or flocculent, low density properties. 
 Drugs with better taste, objectionable odour, sensitivity towards oxygen or 
hygroscopic nature may require encapsulation/entrapment prior to compression, or 
coating of tablets is required. 
 Elderly, ill and children could have problem in swallowing the tablets. 
 Drugs with poor wetting and slow dissolution properties may be difficult to formulate 
or manufacture as a tablet that will still provide adequate or full drug bioavailability. 
TYPES OF TABLETS
6
 
Tablets are divided into classes based on their route of administration and their function. 
1. TABLETS ADMINISTERD ORALLY 
A. Compressed tablets 
 Sugar coated tablets  
 Film coated tablets  
 Enteric coated tablets 
 Chewable tablets 
 Controlled release tablets 
B. Multiple compressed tablets 
 Layered tablets 
 Press coated tablets 
2. TABLETS ADMINISTERED IN ORAL CAVITY 
A. Buccal and sublingual tablets 
B. Lozenges and trouches 
C. Dental cones 
3. TABLETS ADMINISTERED VIA OTHER ROUTES 
A. Implants 
B. Compressed suppositories or inserts 
C. Vaginal tablet 
 
 
1. Introduction 
 
Department Of Pharmaceutics, Madras Medical College Page 4 
 
4. TABLETS ADMINISTERED IN SOLUTION FORM 
A. Effervescent tablets  
B. Dispensing tablets 
C. Hypodermic tablets 
D. Tablet triturates 
MULTILAYER TABLETS 
       Multilayer tablets are made by compressing several different granulations fed into die in 
succession, one on top of another, in layers. Each layer comes from a separate feed frame 
with individual weight control. Rotary tablet process can be set up for two or three layers. 
More are possible but the design becomes very special. Ideally, a slight compression of each 
layer and individual layer ejection permits weight checking for control purpose. 
ADVANTAGES OF MULTILAYER TABLETS 
 Incompatible substances can be separated by formulating them in separate layers as a 
two-layer tablet or separating the two layers by a third layer of an inert substance as a 
barrier between the two. 
 Two layer tablets may be designed for sustained release one layer for immediate 
release of the drug and the second layer for extended release, thus maintain a 
prolonged blood level. 
 Layers may be coloured differently to identify the product. 
 
BILAYER TABLET
7 
Bi-layer tablet is a unit compressed tablet dosage form intended for oral application. It 
contains two layers in which one layer having conventional or immediate release part of 
single or multiple active ingredients, another layer is sustained or controlled release part of 
single or multiple active ingredients. 
Bi-layer tablets are novel drug delivery system where combination of two or more 
drugs in single unit having different release profiles improves the patient compliance, 
prolongs the drug action, resulting in effective therapy along with better control of plasma 
drug level. 
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Bi-layer tablet is suitable for sequential release of two drugs in combination, separate 
two incompatible substances, and also for sustained release tablet in which one layer is 
immediate release as initial dose and second layer is maintenance dose. 
Nowadays various developed and developing countries move towards combination 
therapy for treatment of various diseases and disorders requiring long term therapy such as 
hypertension, diabetes and cardiovascular diseases. Combination preparation plays an 
important role in clinical treatment because of its better and wider curative synergism and 
weaker side effects. Combination therapy may be achieved by giving separate drugs or where 
available by giving combination drugs (monolithic or bilayer dosage form) which are dosage 
forms that contain more than one active ingredient. 
ADVANTAGES 
They are used as an extension of a conventional technology 
 Ability to combine different release rate. IR and SR in the same tablet for chronic 
condition requiring repeated dosing. 
 Promoting patient convenience and compliance because fewer daily doses are 
required compared to traditional delivery system. 
 Two different drugs in same dosage form. 
 Separation of incompatible components thus minimizes the physical and chemical 
incompatibilities. 
 Solve degradation problem. 
 Reduce pill burden to patient. 
 Maintain physical and chemical stability. 
 Retain potency and ensure dose accuracy. 
ADVANTAGES OF BI-LAYER TABLETS OVER CONVENTIONAL TABLETS 
 Blood level of drug can be held at consistent therapeutic level for improved drug 
deliver, accuracy, safety and reduce side effects. Reduction of adverse side effects can 
be accomplished by targeting the drug release to the absorption site as well as 
controlling the rate of release, enabling the total drug content to be reduced. 
 Patient convenience is improved by fewer daily doses are required compared to 
traditional system. Patient compliance is enhanced leading to improved drug regimen 
efficacy. 
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 Bilayer tablets are readily lend themselves to repeat action products, where in one 
layer on layered tablet provides the initial dose, rapidly disintegration in the stomach, 
the layer are insoluble in gastric media but released in the intestinal environment. 
 Separate physically and chemically incompatible ingredients. 
DISADVANTAGES 
 Inaccurate individual layer weight control. 
 Cross contamination between the layers. 
 Insufficient hardness. 
 Reduced yield. 
 Adds complexity and bi-layer rotary presses are expensive. 
TYPES OF BILAYER TABLET PRESS 
1. Single sided tablet press 
2. Double sided tablet press  
3. Bi-layer tablet press with displacement monitoring 
SINGLE SIDED TABLET PRESS 
 The simplest design is a single sided press with both chambers of the doublet feeder 
separated from each other. 
 Each chamber is gravity or force fed with different powers, thus producing the 
individual layers of the tablets. 
 When the die passes under the feeder, it is at first loaded with the first layer powder 
followed by the second layer powder. 
 Then the entire tablet is compressed in one or two steps. 
LIMITATIONS 
 No weight monitoring/control of the individual layers. 
 No distinct visual separation between the two layers. 
 Very short first layer dwell time due to the small compression roller, possibly 
resulting in poor de-aeration, capping and hardness problems. 
 This may be corrected by reducing the turret-rotation speed (to extend the dwell time) 
but with the consequence of lower tablet output. 
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 Very difficult first layer tablet sampling and sample transport to a test unit for in-line 
quality control and weight recalibration. 
DOUBLE SIDED TABLET PRESS 
 Most double sided tablet presses with automated production control use compression 
force to monitor and control tablet weight. 
 The effective peak compression force exerted on each individual tablet or layer is 
measured by the control system at the main compression of the layer. 
 This measured peak compression force is the signal used by the control system to 
reject out of tolerance tablets and correct the die fill depth when required. 
BILAYER TABLET PRESS WITH DISPLACEMENT 
The displacement tablet weight control principle is fundamentally different from the 
principle based upon compression force. When measuring displacement, the control system 
sensitivity does not depend on the tablet weight but depends on the applied pre-compression 
force. 
ADVANTAGES 
 Weight monitoring/control for accurate and independent weight control of the 
individual layers. 
 Low compression force exerted on the first layer to avoid capping and separation of 
the two individual layers. 
 Independence from machine stiffness. 
 Increased dwell time at pre-compression of both first and second layer to provide 
sufficient hardness at maximum turret speed. 
 Maximum prevention of cross contamination between the two layers. 
 Clear visual separation between the two layers and maximized yield. 
VARIOUS TECHNIQUES FO A BI-LAYER TABLET
7,8
 
The techniques are as follows, 
1. OROS® push pull technology 
2. L-OROS tm technology 
3. EN SO TROL technology 
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4. DUROS technology 
5. DUREDASTM technology 
 
1. OROS ® push pull technology 
                          This system consist of mainly two or three layers among which one or 
more layers are the drug and other layer consist of push layer. The drug layer mainly 
consists of drug along with two or more different ingredients. The drug layer consists of 
poorly soluble drug. There is further addition of suspending agent and osmotic agent. A 
semi permeable layer surrounds the tablet core. 
 
 
Fig 1: Bilayer and trilayer OROS push pull technology  
 
2. L-OROS tm technology 
                This system is used for the solubility issue. Alza developed the L-OROS system 
where a lipid soft gel product containing drug in a dissolved state is initially manufactured 
and then coated with a barrier membrane, then osmotic push layer and then a semi 
permeable layer membrane drilled with an external orifice. 
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                                            Fig 2: L –OROS tm technology 
 
 
3. EN SO TROL technology 
                Solubility enhancement of an order of magnitude or to create optimized dosage 
form shire laboratory use an integrated approach to drug delivery focusing on 
identification and incorporation of the identified enhancer into controlled release 
technologies. 
 
 
 
Fig 3: EN SO TROL technology 
4. DUROS technology 
              The system consists of an outer cylindrical titanium alloy reservoir. The reservoir 
has high impact strength and protects the drug molecules from enzymes. The DUROS 
technology is the miniature drug dispensing system that opposes like a miniature syringe 
and release minute quantity of concentrated form in continuous and consistent form over 
months or years. 
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                                                              Fig 4: DUROS technology 
6. DUREDASTM  technology 
             It is a bilayer tablet which can provide immediate or sustained release of two 
drugs or different release rate of the same drug in one dosage form. The tabletting 
process can provide an immediate release granulate and a modified release 
hydrophilic matrix complex as separate layers within one tablet. The modified release 
properties of the dosage form are provided by a combination of hydrophilic polymers. 
Benefits offered by the DUREDAS
TM 
technology includes 
 Bilayer tabletting technology  
 Tailored release rate of two drug components  
 Capability of two different CR formulations combined 
 Capability for immediate release and modified release components in one tablet 
 Unit dose, tablet presentation 
    The DUREDAS
TM
system can be easily manipulated to allow incorporation of two 
controlled release formulation on the bi-layer. Two different release rates can be achieved 
from each side. In this way greater prolongation of sustained release can be achieved. 
 Typically an immediate release granule is compressed first followed by the addition 
of a controlled/sustained release element which is compressed onto the initial tablet. This 
gives the characteristic bi-layer effect to the final dosage form. 
 A further extension of DUREDAS
TM 
technology is the production of controlled 
release dosage forms where by two drugs are incorporated into the different layers and drug 
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release of each is controlled to maximize the therapeutic effect of the combination. Again 
both immediate and controlled release combinations of two drugs are possible. 
PRECAUTIONS TO BE TAKEN TO GET GOOD BILAYER TABLETS 
For good quality tablets with sharp definition between the layers, special care must be 
taken as follows. 
 Dust fines must be limited. Fines smaller than 100 mesh should be kept at a 
minimum. 
 Maximum granule size should be less than 16 mesh for a smooth, uniform scrape-off 
at the die. 
 Materials that smear, chalk or coat on the die table must be avoided to obtain clean 
scrape-off and uncontaminated layers. 
 Low moisture is essential if incompatibles are used. 
 Weak granules that break down easily must be avoided. Excessive amounts of 
lubrication especially metallic stearates should be avoided for better adhesion of the 
layers. 
 Formulation of multilayer tablet is more demanding than that of single layer tablets. 
For this reason, selection of additives is critical. 
IMMEDIATE RELEASE TABLETS
9
 
The term “immediate release” pharmaceutical formulation includes any formulation 
in which the rate of release of drug from the formulation and/or the absorption of drug, is 
neither appreciably, nor intentionally, retarded by galenic manipulations. In the present case, 
immediate release may be provided for by way of an appropriate pharmaceutically acceptable 
diluent or carrier, which diluent or carrier does not prolong, to an appreciable extent, the rate 
of drug release and/or absorption. 
 Immediate release dosage forms are those for which >85% of the labeled amount 
dissolves within 30minutes. For immediate release tablets, the only barrier to drug release is 
disintegration or erosion stage which is generally accomplished in less than one hour. To 
enhance dissolution and hence bioavailability of any drug for immediate release tablets, 
disintegration is one of the important process. Few super disintegrants are available 
commercially as croscarmellose sodium, crospovidone and sodium starch glycolate. 
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                Tablets for an immediate release often consist of filler, binder, lubricant and 
disintegrant. In many cases, the disintegration time of solid dosage form is too long to 
provide appropriate therapeutic effect. To improve the disintegration time, disintegrants are 
used. The most accepted mechanisms of their action are wicking, swelling, and deformation 
recovery and particle repulsion. Together, these phenomena create a disintegrating force 
within the matrix. In the past, non modified disintegrants like alginates, starches, amberlite 
resins, cellulose materials, pectins and others were used to accelerate disintegration.  
Today, a fast working superdisintegrant is chemically modified, typically by 
crosslinking the organic chains of a polymeric molecules. Three classes of super disintegrants 
are commonly used. Modified cellulose (croscarmellose sodium – Ac-Di-Sol®, Vivasol®), 
crosslinked polyvinyl-pyrrolidone (polyplasdone® XL – 10) and modified starch (sodium 
starch glycolate - Primojel®, Explotab®). 
 
CONTROLLED DRUG DELIVERY SYSTEMS
10, 11
 
 It includes any drug delivery system which releases the drug predetermined rate over 
an extended period time. 
            Over the Past 30 years, as the expense and complications involved in marketing new  
drug entities have increased, with concomitant recognition of the therapeutic advantages of 
Sustained drug delivery, greater attention is being paid on development of oral sustained 
release drug delivery systems.  
           The goal in designing sustained release drug delivery system is to reduce the 
frequency of the dosing, reducing the dose & providing uniform drug delivery. So, Sustained 
release dosage form that releases one or more drugs continuously in predetermined pattern 
for a fixed period of time, either systemically or locally to specified target organ. Sustained 
release dosage forms provide better control of plasma drug levels, less dosage frequency, less 
side effect, increased efficacy and constant delivery. 
          This is usually accomplished by attempting to obtain zero order release from the 
dosage form. Zero order release constitutes drug release from the dosage form that is 
independent of the amount of the drug in the delivery system (i.e., a constant rate). 
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                Sustained release generally do not attain this type of release and usually try to 
mimic zero order release providing drug in a slow first order fashion (i.e., concentration 
dependent). 
                Systems that are designated as prolonged release can be considered as attempts at 
achieving sustained release delivery. Repeat action tablets are a method of sustained release 
in which multiple doses of a drug are continued within the dosage form and each dose is 
released at a periodic interval. Delayed release systems, in contrast, may not be sustaining. 
Since often the function of these dosage forms is to maintain the drug within the dosage form 
for some time before release. Commonly the release rate is not alteredand does not result in 
sustained delivery, once drug release has begun. Enteric coated tablets are example of such 
type of dosage form. 
              Controlled release, although resulting in a zero order delivery system, may also 
incorporate methods to promote localization of the drug at an active site. In some cases, a 
controlled release system will not be sustaining, but will be concerned strictly with 
localization of the drug. Site-specific systems and targeted delivery systems are the 
descriptive terms used to denote this type of delivery control. 
GENERAL PRINCIPLE OF CONTROLLED RELEASE SYSTEMS
12
 
 The ideal of providing an exact amount of drug at the site of action for a precise time 
period is usually approximated by most systems. This approximation is achieved by creating 
a constant concentration in the body or an organ over an extended period of time; in other 
words, the amount removed from the system. All forms of metabolism and excretion are 
included in the removal process: urinary excretion, entero hepatic recycling, sweats, faecal 
and so on. Since for most of the drugs these elimination processes are first order, it can be 
said that at certain blood level, the drug will have specific rate of elimination. This idea is to 
deliver drug at the exact rate for an extended period. This is represented mathematically as 
Rate in = Rate out =Kelim x Cd x Vd 
Where, Cdis the desired drug level, Vdis the volume of distribution and Kelim is the rate of 
drug elimination from the body. Often such exacting delivery proves to be difficult to achieve 
administration routes other than intravenous infusion. Non invasive routes (e.g., oral) are 
obviously preferred. 
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Fig 5: Ideal Plasma concentration versus time profile showing differences between zero 
order controlled release, slow first order sustained release, and immediate release. 
The pharmacological effect is seen as long as the amount of drug is within the 
therapeutic range. Problems occur when peak concentration is above or below this range, 
especially for drugs with narrow therapeutic windows. 
The slow first order release obtained by sustained release preparation is generally 
achieved by slowing the release of drug from a dosage form. In some cases this is 
accomplished by a continuous release process; however system that release small bursts of 
drug over a prolonged period can mimic the continuous system. 
SUSTAINED RELEASE DRUG DELIVERY SYSTEM
14, 15
 
It  includes any drug  delivery  system achieves  release  of  drug  over  an  extended 
period  of time, which not depend on time. Hydrophilic polymer matrix is widely used for 
formulating an Sustained dosage form. The  role  of  ideal  drug  delivery  system  is  to 
provide  proper  amount  of  drug  at  regular time  interval  &  at  right  site  of  action  to 
maintain therapeutic range of drug in blood plasma. 
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Fig 6: Formulation strategy for oral sustained release drug delivery system 
The IR drug delivery system lacks some features like dose maintenance, sustained 
release rate & site targeting. The oral Sustained drug delivery has some potential advantage 
like Sustained release rate & dose maintenance in plasma. The SR formulations have some 
swelling polymer or waxes or both which controls the release rate. The use of reservoir 
system is also well known for controlling release rate. The IR drug delivery system lacks 
some features like dose maintenance, sustained release rate & site targeting. The oral 
Sustained drug delivery has some potential advantage like Sustained release rate & dose 
maintenance in plasma. The SR formulations have some swelling polymer or waxes or both 
which controls the release rate. The use of reservoir system is also well known for controlling 
release rate. 
Advantages 
Sustained/Controlled release products offer many potential benefits over the 
conventional dosage forms. 
 Reduced dosing frequency. 
 Dose reduction.  
 Improved patient compliance.  
 Constant level of drug concentration in blood plasma.  
 Reduced toxicity due to overdose.   
 Reduces the fluctuation of peak valley concentration.  
 Night time dosing can be avoided. 
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Disadvantages 
 Sustained release products contain a higher drug load and thus any loss of integrity of 
the release characteristics of the dosage form has potential problems. 
 The larger size of sustained release products may cause difficulties in ingestion or 
transit through the gut. 
 Sustained release products may cause decreased systemic bioavailability in 
comparison to conventional dosage forms, which may be due to incomplete release, 
increased first pass metabolism, increased instability, insufficient residence time for 
complete release, site specific absorption, pH dependent stability etc. 
 Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus increased risk of 
toxicity. 
RELEASE MECHANISM FOR SUSTAINED AND CONTROLLED RELEASE 
SYSTEM
13
 
 Based on the release mechanism these are classified as follows, 
 Diffusion controlled system 
 Dissolution controlled system 
Diffusion controlled system 
               In these systems, there is a water soluble polymer, which controls the flow of water 
and the subsequent release of dissolved drug from the dosage form. Diffusion occurs when a 
drug passes through the polymer that forms the controlled release device. The diffusion can 
occur through the pores in the polymer matrix or by passing between polymer chains. These 
are broadly classified into two categories. 
1. Diffusion reservoir system 
2. Diffusion matrix system 
The basic mechanisms of drug release from these two systems are fundamentally different. 
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Diffusion reservoir system 
               In  this system,  a  water  insoluble  polymeric material  covers  a  core  of  drug.  
Drug  will partition  into  the  membrane  and  exchange with  the  fluid  surrounding  the  
particle  or tablet.  Additional  drug  will  enter  the polymer,  diffuse  to  the  periphery  and 
exchange  with  the  surrounding  media. The drug release takes place by diffusion 
mechanism. 
 
                      Fig 7:Schematic representation of diffusion type reservoir system 
Diffusion matrix system 
                  The matrix system is defined as a well-mixed composite of one or more drugs 
with gelling agent i.e. hydrophilic polymers. Matrix systems are widely used for sustaining 
the release rate.   
                   It is the release system which prolongs and controls the release of the drug that is 
dissolved or dispersed. A  solid drug is dispersed in an insoluble matrix and the rate of release  
of  drug  is dependent on the rate of drug diffusion  and  not  on  the  rate  of solid dissolution. 
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                         Fig 8: Schematic representation of diffusion matrix system 
Dissolution controlled system 
                  A  drug  with  a  slow  dissolution  rate  is inherently  sustained  and  for  those  
drugs with high water solubility, one can decrease dissolution  through  appropriate  salt  or 
derivative  formation.  These  systems  are most  commonly  employed  in  the production  of  
enteric  coated  dosage  forms. To protect  the  stomach  from  the  effects  of drugs  such  as  
Aspirin,  a  coating  that  dissolves  in  natural  or  alkaline  media  is used.  This  inhibits  
release  of drug  from  the dosage  form until  it  reaches  the  higher pH of  the  intestine. 
                 In  most  cases,  enteric coated  dosage  forms  are  not  truly sustaining  in  nature,  
but  serve  as  a  useful function in directing release of the drug to a required site.  The same 
approach can be employed for compounds that are degraded by the harsh conditions found in 
the gastric region. 
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2. LITERATURE REVIEW 
REVIEW FOR BILAYER TABLETS 
1.Deepika K L et al.,
16
 designed and evaluated the sustained release bilayer tablets of 
Domperidone Maleate. The tablets were prepared by wet granulation method using 
Croscarmellose sodium as super disintegrant for the immediate release layer and the 
hydrophilic matrix formers such as HPMC K4M, HPMC K 100 M and Carbopol 974 NF for 
the sustained release layer. Bilayer tablet showed as initial burst effect to provide dose of 
immediate release layer, followed by sustained release of Domperidone for 12 hours. The 
data obtained from in vitro release study were fitted to various mathematical model like zero 
order, First order, Higuchi model and Peppas model. The results of mathematical model  
fitting  of  data  obtained  indicated  that,  the  best  fit model in all the cases the release was 
found to be by diffusion and nonfickian release. 
2. Kotta Kranthi Kumar et al.,
17
 formulated and evaluated the sustained release bilayer 
tablets of Pioglitazone hydrochloride for immediate release using cross Povidone as super 
disintegrant and Metformin hydrochloride for sustained release using poly ethylene oxide 
(PEO-303) as matrix forming polymer. The tablets were prepared by direct compression 
technique and Wet granulation technique. The release kinetics of Metformin hydrochloride 
was evaluated using the regression coefficient analysis.  The  formulated  tablets  shows  first  
order  release  and  diffusion  was  the  dominant  mechanism  of  drug  release. Thus 
formulated bilayer tablets proved immediate release of Pioglitazone and Metformin HCl as 
sustained release over a period of 12 hours. 
3. Ashraful Islam S M et al., 
18
 formulated and evaluated of bilayer tablets consisting of 
Paracetamol and Aceclofenac for immediate drug release. Bilayer tablets are prepared by wet 
granulation technique by using sodium starch glycolate (SSG) as super  disintegrant  sodium  
lauryl  sulphate  (SLS)  as surfactant  to  promote  drug  release.  The amount of Paracetamol 
and Aceclofenac released at different time intervals were estimated by HPLC method. 
Dissolution results of all the tablet formulations were analyzed with dissolution efficiency (% 
DE). These results indicated that release of the drug from the tablet was influenced by content 
of super disintegrants and surfactants. Maximum drug release was found in tablets containing 
4% SSG with 4% SLS. So, bilayer tablets could be a potential dosage form for delivering 
paracetamol and aceclofenac. 
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4. Chitra Karthikeyini et al., 
19
 formulated and evaluated of the sustained release bilayer 
tablet of Aceclofenac sodium using superdisintegrant, sodium starch glycolate for the fast 
release layer and water immiscible polymers such as EudragitRL100 for the sustaining layer. 
The bilayer tablets of Aceclofenac sodium were prepared by direct compression method. 
Thedrug release from formulation was found to zero order kinetics. It was also found linear in 
Higuchi’s plot which confirms that diffusion is one of the mechanism of drug release .In this 
studied formulation release the drug upto 24hrs. 
5. Mujoriya R Z et al., 
20
 formulated and evaluated the bilayer tablet of Metoprolol 
Succinate Er and Amlodipine Besilate. The formulation were prepared by using different 
polymer (HPMC, Methocel, Carbapol) with different diluents (MCC, Cellulose Phosphate, 
Starch, Croscarmalose Sodium) and wet granulation method. it can be concluded that a stable 
bilayer tablet of Metoprolol succinate ER and Amlodipine besilate can be prepared by using 
HPMC K 15 M and carbomer as a polymer. It was found that the in vitro drug release of 
Metoprolol succinate ER was best explained by first order (r
2
 =0. 9994), as the plots showed 
the highest linearity, followed by Higuchi’s equation (r2 = 0.9974) and zero-order (r2 = 
0.9471). 
6. Nabin Karna et al., 
21
 designed and evaluated of novel sustained release bilayer tablets of 
Lornoxicam based on the combination of hydrophilic matrix formers and basic Ph modifiers. 
These tablets were prepared by wet granulation technique using basic pH modifiers like 
sodium bicarbonate & magnesium oxide to create basic micro-environmental pH inside 
&give a favorable acidic condition for tablets to release the drug. Different types and levels 
of hydrophilic matrixing agents, like HPMC K4 & HPMC K 15 were used to control the 
release of the drugs. 
7. Chandrashekhar L. Bhingare et al., 
22 
formulated and evaluated the bilayer tablets of 
Atenolol and Hydochlorthiazide. The  bilayered  tablets  gives  biphasic  drug  release  like  
loading  dose  of HCTZ  and  maintenance  dose  of Atenolol.  The  bilayered  tablets  are 
prepared  using  croscarmellose  sodium  as  superdisintigrant  for immediate released  layer 
and different viscosity grades of  hydrophilic polymers  for  sustained  released  layer. In  this  
study,  formulation made  up  from  10%  CCS,  and  formulation made up from intra-
granulation  techniques  and  30mg  blend  of  polymers  releases  the  total drug content at 
the end of the 60 minutes and 12 hrs respectively. The release data obtained from the 
dissolution study of bilayered tablets are analyzed with  respect  to  zero  order,  first  order,  
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Higuchi,  Korsmeyer-Peppas  models  and release  kinetic  is  fitted  to  Korsmeyer-
peppasequation.  The  mechanism  of  drug  release  was regarded  as  anomalous  diffusion  
of  drug  from  matrix. 
8. Brito Raj S et al., 
23 
designed and evaluated the sustained release bilayer tablets of 
Metformin Hydrochloride and Metaprolol tartrate. Bilayer tablets were prepared by wet 
granulation technique using release retarding agents like HPMC K100, Eudragit S 100 for 
sustained release (SR) layer and super disintegrants like Crosspovidone, Sodium starch 
glycolate (SSG) for immediate release (IR) layer.All the formulations obey Zero order release 
kinetics and the mechanism of drug release was found to be non& fickian diffusion by 
fittingthe data to peppas equation. 
9. Soham Shukla et al., 
24
 formulated and evaluated the bilayer tablets of Telmisartan and 
Amlodipine Besilate both as immediate release layersusing full factorial design. Telmisartan 
layer (220 mg) and Amlodipine besilate layer (100 mg) were prepared by wet granulation 
method using various superdisintegrants and binders. Both  Telmisartan  and  Amlodipine  
besilate  layers  were  optimized  using  3
2
  factorial  design. All  formulations  were  
evaluated  for in  vitro drug  release  analyzed  according  to  various release kinetic models. 
Results shows that formulation optimized in Telmisartan layer which contained meglumine 
7.5 % (16 mg) and crospovidone 5 % (11 mg) and formulation optimized in amlodipine 
besilate layer which contained starch paste 5 % (5 mg) and croscarmellose sodium 3% (3 
mg). 
10. Kotta Kranthi Kumar et al., 
25
designed and characterized the sustained release bilayer 
tablets of Metformin hydrochloride and Gliclazide. Tablets were prepared by wet granulation 
method using HPMC as a release retardant. The best formula was selected by dissolution 
profile of Metformin hydrochloride was 101% and Gliclazide was 99% after 24 hours  and  
similarity  factor correlation  studies 70.9%  for  Metformin  hydrochloride  and  67.2%  for  
Gliclazide when compared with the innovater products. 
11. Patel N et al., 
26 
formulated and evaluated the bilayer tablets Telmisartan and 
Hydrochlorthiazide. The bilayer tablets were prepared by wet granulation technique. 
Telmisartan was converted to its sodium salt by dissolving in aqueous solution of sodium 
hydroxide to improve solubility and drug release. The tablets were formulated with high 
proportion of sodium starch glycolate showed that 101.11% and 99.89% respectively. 
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12. Mohamed Halith S et al.,
27
 formulated and evaluated the bilayer tablets of Amlodipine 
besilate and Metprolol succinate In  the  formulation  of  immediate  release  sodium  starch  
glycolate and  pregelatinised  starch  were  used  as  super  disintegrant  and  was  directly  
compressed.  For sustained  release  portion  HPMC  polymers  were  used  in  granulation  
stage  and  also extragranularly. It was found that the optimized formulation showed 9.96%, 
35.56%, 52.12%, 90.46% release for Metoprolol succinate in 1, 4, 8, 20 hours respectively. 
However, Amlodipine besilate released 98.28% at the end of 30 minutes. The kinetic studies 
of the formulations revealed that diffusion is the predominant mechanism of drug and release 
follows first order kinetics. 
13. Mandeep Sharmaet al., 
28 
developed and Characterized the bilayer tablet Containing 
Metformin Hydrochloride in sustained release layer and Atorvastatin Calcium in immediate 
release layer. Bilayer tablets were prepared by wet granulation technique. The atorvastatin 
showed burst release whereas Metformin had sustained released. After  20 minutes,  the  
Atorvastatin  was  completely released  from  formulation whereas  for others  drug  release  
was  less  than  80  %.  The steady  state  concentration  of  Metformin  for  all formulation  
was  reached  within  2-3h. The in vitro release  studies  data  was  quantified  to determine  
the  release  mechanism,  to  fit  various mathematical  models  and  to  determine  which the  
best-fit  model studied  was zero order, first order and Higuchi model. The correlation  
coefficient  was  found  to  be equal  to  one  for  first  order  model.  So, the developed 
tablets showed first order release behaviour. 
14. Ch.Anil Kumaret al., 
29
formulated and evaluated the bilayer tablet of Metformin HCl 
and Glimepiride HCl of which Metformin HCl as sustained release and Glimepiride as 
immediate release layer.  Sustained  layer  were  prepared  by  wet granulation method using 
Eudragit’s  as polymers,  immediate  release layer  were  prepared by direct  compression 
method using super disintegrants such as cross carmellose sodium and sodium starch 
glycollate. The in vitro release profile of drug from sustained release layer could be expressed 
by higuchi’s equation as pilot show high linearity R2=0.9911and diffusion was the dominant 
mechanism of drug release. The formulation having immediate release layer produces 
immediate effect 94.53 ± 0.30 within 45 minutes followed by sustained release effect 95.77 ± 
0.37 up to 8 hours. 
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15. Jyotsna Godbole et al.,
30
 formulated and evaluated the bilayer matrix tablets  containing  
Acarbose  as  immediate  release component using sodium starch glycolate and cross 
carmillose sodium  as  super  disintegrates  and  Metformin  hydrochloride (HCl)  for  
sustained  release  by  using  hydroxyl  propyl  methyl cellulose  (HPMC  K  4M),  (HPMC K  
100)  and  sodium  carboxyl methyl  cellulose  (SCMC)  as  the  matrix  forming  polymer 
and PVPK-30  as  binder. These release the drug by both as  well  as  diffusion  controlled  
mechanisms the half life of metformin  HCl  is  6.2  hrs,  so  an  attempt  was  made  in  the 
direction of preparation and optimization of a combination of sustained  release  and  
immediate  release  in  a  single  tablet. Tablets were prepared by wet granulation and direct 
compression method. The final preparation showed release of drug up to 96.75 in 8hours. 
16. Rama et al., 
31
 formulated and evaluated the bilayer tablets of two incompatible drugs 
Amlodipine besilate and Losartan potassium. Losartan potassium was prepared by wet 
granulation and Amlodipine besilate by direct compression. Super disintegrants like 
crospovidone, sodium starch glycolate were used in all formulation. The dissolution studies 
showed the drug release 84.02% for Amlodipine besilate and 90.08% for Losartan potassium 
in 30 minutes was selected as optimized formulation. 
17. Margret chandira R et al., 
32
 formulated and evaluated the bilayer floating tablets of 
Metformin Hydrochloride. The tablets were prepared by direct compression technique by 
using HPMC as release retardant, sodium bicarbonate as gas generating agent to reduce 
floating lag time. The in vitro drug release followed zero order kinetics and drug release was 
found to be diffusion controlled. 
18. Ajit Kulkarni et al.,
33
 formulated and evaluated the bilayer regioselective floating tablets 
of Atenolol and Lovastatin  to  give  immediate  release  of  Lovastatin  and  sustained  
release  of  Atenolol.The immediate  release  layer  comprised  sodium  starch  glycollate  as  
a  super  disintegrant  and  the sustained  release  layer  comprised  HPMC  K100M  and  
xanthan  gum  as  the  release  retarding polymers. Sodium bicarbonate was used as a gas 
generating agent. Direct compression method was used for formulation of the bilayer tablets. 
All formulations floated for more than 12 h. More than 90% of Lovastatin was released 
within 30 min. HPMC K100M and xanthan gum sustained retarded the release of Atenolol 
from the controlled release layer for 12 h. Diffusion exponents (n) were determined for all the 
formulations (0.53-0.59). The release of Atenolol was found to follow a mixed pattern of 
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Korsmeyer-Peppas, Hixson-Crowell and zero order release models. The optimized 
formulation was found to be buoyant for 8 h in stomach. 
REVIEW LITEATURE FOR LISINOPRIL 
19. Rajeshree Panigrahi et al., 
34
 formulated and evaluated the fast dissolving tablet of 
Lisinopril. All the superdisintegrants such as crosscarmellose, crosspovidone, sodium starch 
glycolate were maintained in different concentrations in all the formulations. Microcrystalline 
cellulose was used as diluents and also as a superdisintegrant.In vitro drug release showed 
that formula crosspovidone and sodium starch glycolate had better % drug release as compare 
to other formulations. 
20. Ashish Jain et al., 
35
 formulated and evaluated the comparative release study of 
Lisinopril from different topical vehicles. An in vitro diffusion cell experiment was designed 
to reveal the rate of release of Lisinopril from three different topical vehicles: (i) an oil-in-
water cream; (ii) a gel; and (iii) an ointment. Ointment base showed considerably higher drug 
release than other vehicles. 
21. Basawaraj S.Patil et al., 
36 
prepared and evaluated an oral pulsatile drug delivery system 
based on a press coated tablet. The core containing Lisinopril as a bioactive compound was 
prepared by direct compression method. The coating materials consisted of hydrophobic 
polymer of ethyl cellulose and hydrophilic materials (HPMC 15 CPS) were used in different 
concentration. 
22. Anand Padole et al.,
37
 formulated and evaluated the  Buccal  tablets  of  lisinopril  by  
direct  compression  method  using  different  hydrophilic  polymers  such  as hydroxypropyl  
methylcellulose,  sodium carboxy  methylcellulose  and  Carbopol. Drug  release  mechanism  
was  determined  by  plotting  release  data  to  Higuchi  and  Korsmeyer-Peppas  model. 
According to this model the drug releases from theses tablets may be controlled by diffusion. 
23. Pandey Shivanand et al., 
38 
formulated and evaluated the taste masked fast disintegrating 
tablets of Lisinopril. It was concluded that beta cyclodextrins were useful for masking the 
taste as well as enhancing the solubility of the drug. Superdisintegrants were helpful in 
formulation of the Fast dissolving tablets. crosscarmellose Sodium is suitable for this 
formulation. 
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24. Shamsheer Ahmad S et al., 
39
 formulated and Evaluated of Lisinopril Dihydrate 
Transdermal Proniosomal Gels and prepared by coacervation phase separation method. It was 
observed that the gel formulations showed good spreadability and viscosity. Determination of 
vesicle size was found to be 20.10-26.23µm.All  formulations  showed  zero  order  drug  
release  by  diffusion  mechanism.It showed that  Lisinopril  dihydrate  proniosomal  gel  
containing  lecithin, cholesterol and in combination of surfactants like span 20, 40, 60,80  
sustained  release  of  drug  over  a  period  of  24  hrs. 
25. Malpani Amol et al., 
40 
formulated the Lisinopril dihydrate and studied the effect of 
extend of granulation on response variables. Lisinopril dihydrate tablet evaluation parameters 
like particle size distribution as well as drug release by changing the granulation time during 
formulation process. Mixing time, compression force and other can also some important 
variables which can be considered, depend upon formulation and excipients. 
26. Manickam Balamurugan
41
formulated and evaluated the chitosan based bioadhesive 
transdermal drug delivery systems of lisinopril for prolonged drug delivery. It was prepared 
by solvent evaporation technique with different concentrations of chitosan without any 
penetration enhancers. In-vitro permeation studies were performed in cadaver skin and rat 
skin by using modified Franz diffusion cells. The results followed  Higuchi  kinetics  
(R
2
=0.98),  and  the  mechanism  of  release  was  diffusion  mediated. 
27. Izhar Kasid et al., 
42 
developed and evaluated the bilayer tablets of lisinopril and 
Gliclazide. Both were prepared by direct compression technique. Lisinopril was formulated 
as fast dissolving layer using sodium starch glycolate, croscarmellose sodium as 
superdisintegrants. The optimized lisinopril fast dissolving layer (L-6) with highest in vitro 
release of 99.73% was selected. Gliclazide  was  formulated  as  sustained  release  layer  
using  different  polymer  matrix  like hydroxyethylcellulose, hydroxypropylcellulose, and 
ethylcellulose and evaluated for physical parameter along with in vitro release studies. The 
optimized sustained release layers (G-5) which extend the gliclazide release more than 8hrs 
was selected. The in vivo antidiabetic activity suggested that lisinopril potentiate 
hypoglycemic effect of gliclazide and blood glucose level was constantly maintained upto 
24h. 
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REVIEW LITERATURE FOR GLIPIZIDE 
28. Chakraborty Manas et al., 
43 
prepared Glipizide sustained release and immediate release 
bilayer matrix tablet by different concentration of Hydroxypropyl methylcellulose and Ethyl 
Cellulose to control the release pattern. The sustained release layer of Glipizide was prepared 
by using different grades of HPMC like, HPMC K-100, HPMC K-50 and Ethyl Cellulose 
along with other excipients bywet granulation technique. The  immediate  release  layer  of  
Glipizide  was  prepared  by  Lactose  and  Sodium  starch glycolate by wet granulation 
Method. The release rate of Glipizide in immediate release layer was studied for 1h in pH 7.4 
phosphate buffer media and that of Glipizide in sustained release layer was studied for 10 h in 
pH 7.4 phosphate buffer media. The dissolution release showed that  showed  good  release  
behaviour  91.92%  of  drug  is  released  over  10  hours  and  r
2 
value  is  0.977  in  zero-
order kinetics. 
29. N.G.Raghavendra  Raoet al.,
44
 formulated and evaluated the controlled release zero 
order release Glipizide bilayer matrix tablet using different grades of natural and synthetic 
polymers such as xanthan gum, guar gum, karaya gum and hydroxyl methyl cellulose as 
novel release modifiers. The tablets were prepared by wet granulation method. The in vitro 
release study was performed in phosphate buffer pH 7.4 upto 12hours. The release data were 
fit into different kinetics model (zero order, fist order and korsemeyer-peppas powers law 
equation). 
30. Hitendra S Mahajan et al., 
45
 formulated and evaluated the immediate release Glipizide 
liquidsolid tablets using Avicel PH-102 and Aerosil 200 as a carrier and coating material 
respectively to increase the dissolution rate of poorly soluble Glipizide. Gellan gum also used 
as a disintegrant. The results obtained shows that all Glipizide liquidsolid tablets exhibits 
higher dissolution rate than marketd tablets. Dissolution rate increases with increasing 
concentration of liquid vehicles and maximum drug release achieved by formulation 
containing polyethylene glycol 400 as a liquid vehicle. 
31. BC Behera et al., 
46 
formulated and evaluated the microencapsulated Glipizide produced 
by the emulsion-solvent evaporation method. Microspheres were prepared using 
polymethacrylate polymers (Eudragit® RS 100 and RL 100) by solvent evaporation method 
and characterized for their micromeritic properties and drug loading, as well as by Fourier 
transform infrared spectroscopy (FTIR) and scanning electron microscopy. In vitro release 
studies were performed in phosphate buffer (pH 7.4).  The resulting microspheres obtained 
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by solvent evaporation method were white and free flowing in nature. The mean particle 
sizeof microspheres ranged from 420 - 660 µ m and the encapsulation efficiencies ranged 
from 40.27 - 86.67 %.The mechanism of drug release from the microspheres was found to be 
non-Fickian type. 
32. Bhavani Boddeda et al.,
47
 formulated and evaluated the sustained release tablet 
formulation of glipizide by employing two hydrophobic polymers (ethyl  cellulose and 
ethylene vinyl acetate  copolymer) and two natural hydrophilic gum resins olibanum resin 
and colophony). Different batches of glipizide sustained release tablets were prepared by 
using lactose and dicalcium phosphate as diluents by wet granulation technique.The 
independent model method, Lin Ju and Liaw’s difference factor (ƒ1) and similarity factor 
(ƒ2) were used to compare various dissolution profiles. The kinetics of drug release was best 
explained by Korsmeyer and peppas model and the mechanism of drug release from these 
tablets was by non-fickian diffusion mechanism. 
33. Jinal Patel et al.,
48
formulated and evaluated the floating tablets of  Glipizide  were  
prepared by using different  polymers  like  HPMC  K100M,  sodium  alginate, Carbopol  
940, and PVP K30 by effervescent technique. Sodium bicarbonate and citric acid were 
incorporated as a gas generating agent. Floating tablets containing glipizide were prepared by 
direct compression technique. All the prepared batches showed good in vitro buoyancy.  The 
tablet swelled radially and axially during in vitro buoyancy studies. The dissolution release 
study observed that the tablet remained buoyant for 16-24 hours. 
34. M Sivabalan et al., 
49 
formulated and evaluated hydrodynamically balanced controlled 
drug delivery system of Glipizide.The tablets were prepared by direct compression method 
by using various polymerslike HPMC, MC and EC. The in-vitro release was found to be in 
the range of 59.25% to 79.50%. 
35. J. L. Ramabargavi et al., 
50
 formulated and evaluated the floating matrix tablets of 
Glipizide were prepared by Effervescent floating technique. The formulations  were  prepared  
by polymers  HPMC  5cps  and carbopol  940  used  for  matrix  system,  and  incorporating  
NaHCO3  into  tablets.  Tablets  were  formulated  with  different  ratios  of  HPMC  5cps  
and carbopol  940  individually  and  combination  of  polymers.Different  kinetic  models  
were  applied  to  optimized formulation the  ‘n’  value  is  0.333,  r2  value  is  0.918 
indicating  Fickian  Diffusion  and  first  order  release. 
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                                              3. AIM AND PLAN OF WORK 
AIM OF THE PROJECT WORK 
 To provide effective, safe and stable pharmaceutical oral formulation containing 
antihypertensive drug Lisinopril as immediate release layer and oral antidiabetic 
drug Glipizide as sustained release layer for effective treatment of diabetes along 
with diabetic hypertension and nephropathy. 
 To optimize immediate release tablets of Lisinopril by wet granulation method using 
various concentration of sodium starch glycolate as super disintegrant. 
 To optimize sustained release tablets of Glipizide by wet granulation method using 
ethyl cellulose and swellable polymer HPMC K100M in different ratios. 
 To formulate and evaluate the bi-layer tablets from the optimized batches of 
immediate release and sustained release formulations. 
PLAN OF WORK 
 Preformulation studies  
 Raw material analysis 
 Physical and chemical compatibility studies 
 Construction of calibration curve 
 Precompression studies of the drug, blend and Immediate release granules 
 Bulk density 
 Tapped density 
 Angle of repose  
 Carr’s index 
 Hausner’s ratio 
 Formulation of Lisinopril immediate release(IR) tablets 
 Post compression studies of Immediate release tablets for physical parameters like 
 Uniformity of weight  
 Physical appearance  
 Thickness, hardness and diameter 
 Friability 
 Determination of drug content of IR tablets 
 Disintegration studies of IR tablets 
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 Evaluation of in vitro dissolution study of IR tablets 
 Precompression studies of the drug, blend and SR granules 
 Bulk density 
 Tapped density 
 Angle of repose 
 Carr’s index 
 Hausner’s ratio 
 Formulation of sustained release (SR) tablets 
 Post compression study of SR tablets for physical parameters like 
 Uniformity of weight 
 Physical appearance  
 Thickness & hardness 
 Length & diameter 
 Friability 
 Determination of drug content of SR tablets 
 Evaluation of in vitro dissolution study of SR tablets 
 Formulation of bilayer tablets from the optimized batches of IR and SR layer 
 Post compression study of bilayer tablets for physical parameters like 
 Uniformity of weight  
 Physical appearance 
 Thickness & hardness 
 Length & diameter 
 Friability 
 Determination of drug content by simultaneous equation method 
 Evaluation of in vitro dissolution study of bilayer tablets by simultaneous 
equation method 
 Evaluation of release kinetics of optimized bilayer formulation 
 Determination of stability of bilayer tablets as per ICH guidelines 
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                                     4. RATIONALE OF THE STUDY 
RATIONALE FOR SELECTION OF LISINOPRIL 
Lisinopril is the Lys analog of enalaprilat; unlike Enalapril, Lisinopril itself is active. 
Lisinopril is slightly more potent than enalaprilat. Lisinopril is absorbed slowly, variably, and 
incompletely (about 30%) after oral administration. 
The RAS is involved in a wide range of adverse effects that contribute to metabolic 
diseases. ACE‑I are  effective  as  antihypertensive  agents,  have  utility in  prevention  of  
cardiac  remodeling  following myocardial infarct (MI), inhibition of heart and kidney 
disease, prevention of diabetes, and their use has even been associated with decreased 
mortality in patients hospitalized with community‑acquired pneumonia.ACE‑I  therapy  is  
now  commonly  prescribed  to diabetic patients and has been associated with a lower 
likelihood of other complications including a history of  cancer  and  peptic  ulcers.  Also, 
clinical studies have detected inhibition of diabetic retinopathy by ACE‑I. Lisinopril in 
Insulin Dependent Diabetes Study Group investigated the effect of the ACE‑I, Lisinopril, on 
retinopathy in normotensive type I diabetic patients. They  found  a  50%  reduction  in  the  
progression  of retinopathy  in  lisinopril  treated  subjects  compared to  controls. 
National  guidelines  recommend  ACE‑I therapy  in  patients  with  diabetes  who  
also  have hypertension and/or proteinuria to retard the progression of renal damage. One of 
the main characteristics of essential hypertension is nephrosclerosis, the first clinical sign of 
which is protein in the urine. Proteinuria is  the  main  predictor  of  cardiovascular  disease  
in patients with type 2 diabetes as well as progressive renal disease in type 1 diabetes and in 
patients with overt  diabetic  nephropathy. 
RATIONALE FOR SELECTION OF GLIPIZIDE 
Glipizide is a second generation sulfonylureas, an oral hypoglycemic agent for the 
management of non-insulin dependent diabetes mellitus.The half life of Glipizide is 2-5 
hours;hence it is a suitable candidate for the design of sustained release drug delivery 
system.On a weigth basis, Glipizide is 100 times more potent than Tolbutamide. It has more 
rapid onset of effect than glyburide and a shorter duration of action. 
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Glipizide reduces blood glucose by stimulating insulin secretion and altering insulin 
sensitivity, the drug causes a sustained increase in glucose stimulated insulin secretion in 
most patients during prolonged therapy. 
It improves glucose utilization not only by promoting pancreatic insulin release but 
also by enhancing extra pancreatic availability of insulin and the number of insulin 
receptors.By using sustained release dosage form the therapeutically effective concentration 
can be maintained for longer time than the conventional dosage form. 
By the use of sustained release dosage form, saw tooth kinetics of blood levels 
associated with conventional multidosage form can be eliminated and also incident of the 
local and systemic adverse effects can be reduced. 
By using the sustained release dosage form Glipizide has minimal side effects and 
safer drug to diabetes. 
RATIONALE FOR SELECTION OF LISINOPRIL AND GLIPIZIDE FOR 
FORMULATING BILAYER TABLETS 
Most of the patients with type 2 diabetes have  insulin  resistance  is  related  to  
hypertension  and frequently  is  a  comorbidity. Patients with diabetes are more likely to be 
hypertensive than nondiabetics, and hypertension is linked with cardiovascular disease, 
stroke, progression of renal disease, and other complications. The cardiovascular morbidity 
and mortality related to diabetes are very high. 
Proteinuria is  the  main  predictor  of  cardiovascular  disease  in patients with type 2 
diabetes as well as progressive renal disease in type 1 diabetes and in patients with overt  
diabetic  nephropathy. These complications are reduced by bilayer tablet. 
Lisinopril potentiate hypoglycemic effect of Glipizide and blood glucose level was 
constantly maintained upto 24 h. Hence  bilayer  tablets  of  Lisinopril  and  Glipizide as  fast  
and  sustained  release  combination  could  be used  to improve  patient  compliance  towards  
the  effective  management  of  diabetes  along  with  diabetic  hypertension  and 
nephropathy. 
In order to reduce the polytherapy too monotherapy in patients with hypertension and 
type 2 diabetes and improve the patient compliance when two drugs are used in a single 
dosage form rather than taking individual.  
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                               5. DISEASE PROFILE 
DIABETES MELLITUS
51, 52
 
              Diabetes mellitus is a chronic disorder characterized by impaired metabolism of 
glucose.  Diabetes mellitus is a group of disorders involving distinct pathogenic mechanisms 
with hyperglycemia as the common denominator. Regardless of the cause, the disease is 
associated with insulin deficiency, which may be total, partial or relative when viewed in 
respect of co-existing insulin resistance. 
             Diabetes mellitus has reached epidemic proportions and affects more than 170million 
individuals worldwide.  In  more  developed  societies,  the  prevalence  of diabetes  mellitus  
has  reached  about  6%  and even  more  alarmingly, among obese white adolescents 4% had 
diabetes and 25% had abnormal glucose tolerance. Some 90% of diabetic individuals have 
Type-2  (Non-Insulin-dependent)  diabetes mellitus, and within  this  category  no more 
than10%  can  be  accounted  for monogenic forms such as maturity-onset diabetes of the 
young and mitochondrial diabetes or late-onset autoimmune diabetes of the adult, which is 
actually late-onset Type 1 diabetes. Thus, most diabetes in the world is accounted for by 
"common" Type 2 diabetes, which has a multifactorial pathogenesis caused by alterations in 
several gene products. 
CAUSES 
             Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can 
be caused by deficiency of insulin, resistance to insulin or both. People with diabetes have 
high blood sugar. This is because: 
 Their pancreas does not make enough insulin 
 Their muscle, fat, and liver cells do not respond to insulin due to insulin resistance. 
Classification of Diabetes Mellitus
53, 54, 55
 
1.  Type 1 diabetes (beta cell destruction, usually leading to absolute insulin deficiency) 
a) Immune Mediated 
b) Idiopathic 
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2.  Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretary defect with relative insulin resistance). 
3. Other Specific Types 
a. Genetic defects of beta cell function and insulin action 
b. Disease of the exocrine pancreas 
c. Endocrinopathies 
d. Drug induced 
e. Infections 
f. Gestational Diabetes 
 
Fig 9: Metabolic causes of Type 2 diabetes mellitus 
Symptoms of Diabetes Mellitus 
The classical symptoms of diabetes mellitus are: 
 Polydipsia ( Increased intake of water due to increased thirst) 
 Polyuria (Increased formation of urine) 
 Polyphagia (Increased ingestion of food). 
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Diagnosis of Diabetes Mellitus 
                Two  kinds  of  blood  estimations  are  done  to  estimate  the  normal  plasma  
glucose levels. The first one is known as Random Plasma Glucose (RPG) in which a sample 
is drawn at any “random” time during the day without consideration to the “fed” state of the 
patient. The others are samples known as Fasting Plasma Glucose (FPG) followed by Post -
prandial Plasma Glucose (PPG). The patient is advised not to eat anything after dinner till the 
blood sample for FPG is withdrawn the next morning. There  are  three ways  to diagnose  
diabetes each  must  be  confirmed on  a  subsequent day, by any one of the three methods. 
1. FPG> 126mg/dl (0.7 mmol/l), fasting is defined as no caloric intake for at least8hours. 
2. 2-h PPG> 200 mg/dl (11.1mmol/1) during an Oral glucose Tolerance Test (OGTT). 
    The Expert Committee recognizes an intermediate group of subjects whose (FPG>110 
mg/dl (6.1 mmol/l) but < 126mg/d; (7.0 mmol/l) or 2-h values in the OGTT of >140 mg/dl 
(7.8mmol/l)but <200 mg/dl (11.1mmol/l).  Thus, the categories of FPG values are as follows, 
 FPG< 110 mg/dl (6.1 mmol/l) = normal fasting glucose 
 FPG> 110 mg/dl (6.1 mmol/l) and < mg/dl (7.0mmol/l) = FPG 
 FPG> 126 mg/dl (7.0 mg/dl) = provisional diagnosis of diabetes (the diagnosis must 
be confirmed, as described above) 
 
COMPLICATIONS OF DIABETES MELLITUS 
Acute complications Chronic complications 
1. Infections 
2. Diabetic ketoacidosis 
3. Hyperosmolar coma 
 
Micro-vascular 
1. Retinopathy 
2. Neuropathy 
3. Nephropathy 
Macro-vascular 
1. Coronary artery disease 
2. Stroke 
3. Peripheral vascular disease 
4. Non healing ulcer 
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Abnormalities in Beta Cell Function in Type 2 Diabetes 
                Glucose homeostasis that requires a balance between glucose production by the 
liver and  glucose  utilization  by  insulin–dependent  tissues  (such  as  fat  and  muscle)  and 
insulin–independent tissues (such as the brain)., is regulated by insulin production in beta  
cells  and  glucagon  production  in  alpha  cells  of  the  pancreatic  islets.  In Type 2diabetes, 
there are defects in both peripheral tissue responses to insulin and beta cells response to 
glucose. In Type 2 diabetes there are two defects: reduction in the ability of peripheral  
tissues  to  respond  to  insulin  (insulin  resistance)  and  a  relative  insulin deficiency  
resulting  from  an  inability  of  the  beta  cells  to  compensate  for  this resistance. 
Biochemical Changes Associated With Insulin Deficiency 
                Insulin deficiency depresses glucose transport into the cell and glycogen synthesis 
in the muscle. At the same time there is an increase in protein breakdown. Insulin lack leads 
not only to under utilization of glucose at the cellular level but also promotes 
gluconeogenesis. All this lead to hyperglycemia which is associated with polys.  Low  insulin  
levels  leads  to  increased  hormone  sensitive  lipase  activity  in adipose  tissues  cells.  
Long chain fatty acids released are broken down to large quantities of acetyl coenzyme–A, 
which instead of being burnt by the tricarboxylatedacid cycle is diverted to the formation of 
acetoacetate. Acetoacetate is decarboxylated to give acetone or reduced to from beta 
hydroxybutrate. Acetone, acetoacetate and betahydroxy butyric acid are collectively known 
as ketone bodies. Ketone bodies, being volatile are excreted in the breath and in the urine. 
 
                                                      Fig 10: Insulin deficiency 
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Insulin Resistance 
          Insulin resistance is a state in which normal amount of Insulin produces a 
subnormal amount of Insulin response. There is an impaired biological response to insulin by 
one or more of its target tissues leading to reduced glucose disposal. Defects in binding of 
insulin to its receptors due to the reduction in their number or affinity would result in Insulin 
resistance. Clinically insulin resistance stage falls in two categories. 
 Decreased sensitivity:  where normal response can be obtained with supramaximal 
insulin levels. 
 Decreased responsiveness: Even massive doses of insulin cannot produce a normal 
level or response. There is an increase in Hepatic glucose output (which contributes 
primarily to fasting hyperglycemia) and reduction in peripheral glucose utilization.  
There is also elevation of plasma FFA (freefatty acids) resulting from activation of 
lipolysis. 
 
                    Fig 11: Progression insulin resistance towards type 2 Diabetes mellitus 
Management of Type 1 Diabetes 
Insulin therapy 
 Numerous  preparations  of  Insulin  are  available  to  cater  to  the  diverse 
requirements of different patients. The preparations differ in their: 
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1. Onset of action 
2. Duration of action 
3. Purity (Conventional, Purified) 
4. Species of origin (Human, Pork, Bovine–in order of preference) 
Based on their onset and duration of actions, the insulin may be divided into: 
a) Rapid acting 
Insulin Injection (Regular, Crystalline Zinc) 
b) Intermediate Acting 
Isophane (NPH) 70%, Regular Insulin 30%, Isophane (NPH) Insulin Suspension 
c) Long Acting 
Extended Insulin zinc suspension (Ultralente): The intermediate acting 
Isophane(NPH) insulins are conjugated to Protamine, large-protein molecule which delays 
absorption thereby prolonging the duration of action. It is a mixture of 70% ultralenteand30% 
semi-lente. The  long-acting  Ultralente  zinc-insulin  suspension  has  a  large particle size 
and crystalline  form  which  retards  the  rate  of  absorption  and  thus prolongs the duration 
of action. 
Management of Type 2 Diabetes 
The  treatment  of  patients  with  Type  2  diabetes  goes  beyond  normalizing  blood 
glucose  levels; therapy is also directed toward alleviating symptoms, minimizing acute 
complications (e.g., hypoglycemia), increasing the patient’s sense of well-being and  quality  
of  life,  minimizing  chronic  complications  such  as  nephropathy, neuropathy, and 
macrovascular and microvascular disease. The initial therapy in Type2  diabetes  is  nutrition  
and  exercise,  with  a  program  designed  to  encourage  weight loss. The decision to use oral 
glucose- lowering  agents  generally  takes  place  after atrial  period  of  diet  and  exercise.  
To be maximally effective however, a nutritionally correct diet and regular exercise should 
support any pharmacologic intervention. 
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  Among  oral  hypoglycemic  agents  the  older  groups  that means  sulfonylureas  
and biguanies  are  still  extensively  used. Several new drugs have appeared in the recent 
years which act through different mechanisms of action. Their use as monotherapy or in 
combination with other drugs will help to get a better glycemic control. 
 
                               Fig 12: Mechanism of action oral hypoglycemic agents 
Morbidity and Mortality of Type 2 Diabetes Mellitus 
Diabetes mellitus (DM) is the main cause of mortality and morbidity in the developed 
world. The low compliance with the prescribed and self–administered treatments is well 
known to be a great problem in treating chronic disease such as in the case of DM. Patients 
with Type 2 diabetes are prone to both acute and long–term complications. Long–term 
diabetic complications are related to the effects of chronic hyperglycemia on the 
microvasculature. 
Diabetes–related  complications  may  have  grim  outcomes:  Diabetes  is  the leading  
cause of blindness in adults, of end –stage renal disease, and of  non trauma necessitated 
amputations. Retinopathy is seen is 12% to 44% of patients with Type 2diabetes 10 years 
after diagnosis and is present at the time of diagnosis in 10% to 20%of patients. Nephropathy 
leading to end–stage renal failure occurs in 4% to 20% of patients with Type 2 diabetes.  It  is  
well  established  that  Type  2  diabetes  is  an independent risk–factor for cardiovascular 
disease–Type 2 diabetes patients have a2-to 3-fold increase in morbidity and mortality related 
to coronary artery disease, as well as an increased incidence of peripheral vascular disease. In 
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one study examining the  prevalence  of  complications  in  patients  with Type  2  diabetes,  
48%  had  coronary artery  disease,  56%  were hypertensive,  15%  exhibited  signs  of  
cerebrovascular disease and 35% has peripheral artery disease .The  complexity  of  Type  2  
diabetes  and  associated  co-morbidities  will  continue to present a formidable challenge for 
successful pharmacological treatment. 
Perspectives 
Despite the magnitude of the disease, the choice of oral anti hyperglycemic drugs for 
Type 2 diabetes was limited to sulfonylureas for over 40 years. The last 11years have 
witnessed  the  introduction  of  four  new  classes  of  oral  anti hyperglycemic  therapies. 
Each possesses a distinct mechanism of action, which enables their use independently and, in  
some  cases,  as  combination  therapy.  Combination drug therapy is not new. Combinations  
were  frowned  upon  in  much  of  the  20
th
century  because  of  the prevailing philosophy 
was to seek a single “silver bullet” to treat a disease rather than prescribe  multicomponent  
formulations  to  be  dispensed  by  Pharmacist  (or)Physicians. Current guidelines for 
combination therapy advice the use of agents with differing  and  complementary  mechanism  
of  action  which  mainly  arises  in  the treatment  of  diabetes  in  order  to  maximize  
therapeutic  activity  and  reduce  toxicity. This  is  important  since most  patients  with  
Type  2  diabetes  will  require  combination therapy to reach an acceptable level of glycemic 
control. 
Several types of oral diabetes medications, which work to lower blood glucose: 
Sulphonylureas: This family of medications includes Gliclazide, Glimepride and Glipizide. 
These medications are widely recommended for type 2 diabetes and work by stimulating the 
pancreas to release insulin. 
Biguanides: These medications include Metformin and work to improve insulin sensitivity 
and to reduce the glucose produced by liver. 
Acarbose: This type of medication prolongs the absorption of carbohydrates after a meal. For 
these pills to work, they must be taken with or after a meal. 
Thiazolidinediones: This family of medications includes Pioglitazone and Rosiglitazone and 
they work to improve the insulin sensitivity. 
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Meglitinides: This family of medications includes Repaglinide and Nateglinide. They lower 
postprandial (after meal) glucose levels by stimulating the pancreas to release insulin. 
Dipeptidyl peptidase- 4 inhibitors: This family of medications includes Sitagliptin and 
Saxagliptin. They help to improve the insulin release from the pancreas and decrease liver 
release of glucose. 
GLP -1 analog: This class of medications includes Liraglutide, which is a synthetic form of 
the hormone GLP-1. It helps the body release insulin when blood sugar levels are high, and 
also reduces the release of sugar from the liver. It is taken as a daily injection under the skin. 
Hypertension
53
 
Hypertension is defined as sustained elevation of systemic arterial blood pressure. 
Blood pressure is the force, which the blood put against the walls of arteries as it flows 
through them. Arteries are the blood vessels that carry oxygenated blood from the heart to the 
body’s tissue. 
CLASSIFICATION
54, 55
 
Primary hypertension 
It is also called as essential or idiopathic hypertension, affects 90% to 95% of 
hypertensive individuals. 
Secondary hypertension 
It is caused by altered hemodynamics associated with primary disease, such as renal 
disease. Although many diseases causes secondary hypertension, this forms of hypertension, 
this forms of hypertension accounts of 5% to 8% of cases. 
Isolated hypertension 
It is elevated blood pressure accompanied by normal diastolic blood pressure (below 
90mmHg). It is the manifestation of increased cardiac output or rigidity of aorta or both. 
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Risk factors 
For primary hypertension 
 Family history 
 Advancing age 
 Race (most common in blacks) 
 Obesity 
 Tobacco use 
 High intake of sodium or saturated fat 
 Excessive alcohol consumption 
 Life style, stress 
For secondary hypertension 
 Excessive rennin 
 Mineral deficiencies (calcium, potassium and magnesium) 
 Diabetes mellitus 
 Renal artery disease 
 Brain tumor, head injury 
 Cushing’s syndrome 
 Thyroid, pituitary o parathyroid dysfunction 
 Hormonal contraceptive, cocaine, sympathetic stimulants, MAO inhibitors 
 Pregnancy 
PATHOPHYSIOLOGY 
Arterial blood pressure is a product of total peripheral resistance and cardiac output. 
Cardiac output is increased by conditions that increase heart rate or stroke volume or both. 
Peripheral resistance is increased by factors that increase blood viscosity or reduce the lumen 
size of vessels. 
Several mechanisms may lead to hypertension, including 
 Changes in the arteriolar bed causing increased peripheral vascular resistance. 
 Abnormally increases tone in the sympathetic nervous system that originates in the 
vasomotor system centers, causing increased peripheral vascular resistance. 
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 Increased blood volume resulting from renal or hormonal dysfunction. 
 Arteriolar thickening caused by genetic factors, leading to increased peripheral 
vascular resistance. 
 Abnormal rennin release, resulting in the formation angiotensin II, which constricts 
the arteriole and increased blood volume. 
 
 Prolonged hypertension increases the workload of the heart as resistance to left 
ventricular ejection increases. To increase contractile force, the left ventricle hypertrophies, 
raising the oxygen demand and workload of the heart. 
The pathophysiology of secondary hypertension is related to the diseases like, stroke, 
mycordial infarction, heat failure, arrhythmias, retinopathy, encephalopathy and renal failure. 
 
SIGNS AND SYMPTOMS 
 Generally produce no symptoms 
 Occipital headache 
 Epistaxis possibility due to vascular environment 
 Bruits 
 Dizziness, confusion, fatigue 
 Blurry vision 
 Nocturia 
 Edema 
DIAGNOSTIC TEST RESULTS 
 Serial blood pressure measurements show elevation 
 Urine analysis shows protein, casts, red blood cells or white blood cells suggesting 
renal disease, presence of catechlomines associated with pheochromocytoma or 
glucose, suggesting diabetes 
 Blood chemistry reveals elevated blood urea nitrogen and serum creatinine levels 
suggestive of renal disease or hypokalaemia indicating adrenal dysfunction. 
 Excretory urography may reveal renal atrophy, indicating chronic renal disease. 
 Electrocardiography detects left ventricular hypertrophy or ischemia. 
 Chest X-ray shows cardiomegaly. 
 Echocardiography reveals left ventricular hypertrophy. 
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TREATMENT 
 Lifestyle modification to reduce risk factors 
 Diuretics  
 Angiotensin converting enzyme inhibitors 
 Alpha adrenergic receptor blockers 
 Alpha adrenergic receptor agonists 
 Bete adrenergic receptor blockers 
 Treatment of underlying cause 
Role of the Renin-Angiotensin 
56, 57
 
The  Renin-Angiotensin  System  (RAS)  is  an important  component  for  the  
homeostasis  of  blood flow. Renin is released from juxtaglomerular cells of the kidney in 
response to  reduced  renal  perfusion  pressure,  reduced  salt transport  to  the  distal  tubule,  
or  increased  renal sympathetic  tone. 
The action  of  renin  on  its  liver-generated  substrate, angiotensinogen, generates the 
inactive decapeptide, angiotensin  I  (Ang  I),  which  is  hydrolyzed  by angiotensin-
converting  enzyme  (ACE)  to  the octapeptide, angiotensin II(Ang II). ACE conversion of 
Ang I occurs primarily in the lungs, producing changes in Ang II levels that vary in 
accordance to plasma renin levels.  
There is growing evidence that local systems in various tissues and organs are capable 
of generating Ang II including the adrenal gland, brain, heart, kidney, vasculature, adipose, 
gonads, pancreas, prostate, retina, and liver. 
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                       Fig 13: Schematic representation of Renin-Angiotensin cascade 
Ang II is perhaps the most biologically active,  triggering  elevation  in  blood  
pressure  by direct vasoconstriction, the stimulation of thirst by causing vasopressin release, 
and the induction of aldosterone production leading to water retention and  facilitation  of  
sympathetic  activity.  
Ang II has also been implicated in insulin resistance by inhibiting insulin receptor 
dependent PI3K signaling. Additionally, Ang II and can act on the AT1  receptor,  thereby  
decreasing  insulin-induced nitricoxide  production  and  at  the  same  time activating  
NADPH  oxidase  leading  to  enhanced production  of  other  reactive  oxygen  radicals  and 
enhancing inflammation. That hypertension is a common characteristic of insulin-resistant 
diabetes, with observed increases in tissue Ang II seen coupled with the inhibition of the 
vasodilator, nitricoxide, is not surprising.  
Further, it has been shown that  in  diabetic  patients,  therapeutic  inhibition  of the  
RAS  increased  nitric  oxide  activity  in  renal endothelium, having a positive influence on 
renal function,  and  possibly  cardiovascular  function  as well. 
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ACE-I Blockage and Diabetic Complications 
Insulin  resistance  is  related  to  hypertension  and frequently  is  a  comorbidity. 
Patients with diabetes are more likely to be hypertensive than nondiabetics, and hypertension 
is linked with cardiovascular disease, stroke, progression of renal disease, and other 
complications.   
The cardiovascular morbidity and mortality related to diabetes are very high. The 
RAS is involved in a wide range of adverse effects that contribute to metabolic diseases. ACE
‑I are  effective  as  antihypertensive  agents,  have  utility in  prevention  of  cardiac  
remodeling  following myocardial infarct (MI), inhibition of heart and kidney disease, 
prevention of diabetes, and their use has even been associated with decreased mortality in 
patients hospitalized with community‑acquired pneumonia.  
Furthermore, evidence is starting to accumulate for further beneficial uses of these 
drugs in diabetic patients. In spite of the accumulating evidence on the benefits of ACE‑I 
therapy, there is an underuse of ACE‑I in patients with diabetes. 
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                                       6. DRUG PROFILE
61, 62 
 
LISINOPRIL 
Chemical structure  : 
 
Chemical name  :(S)-1-[N
2
-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline   
                                                  dehydrate 
Molecular formula  : C21H31N3O5, 2H2O 
Molecular weight  : 441.5 
Description   : A white crystalline powder 
Melting point   : Melts between 146 ̊C - 148 ̊ C 
Solubility  : Soluble in water. Very slightly soluble in ethanol(95 percent). 
Loss on drying  : Maximum 0.4 per cent, determined on 0.500g by drying in  
                                                  vacuo at 60 ̊ C 
Sulphated ash  : Not more than 0.1 % 
                      Mechanism of action  
 ACE-inhibitors are competitive inhibitors of angiotensin-converting enzyme 
(alsoknown as kininase II). ACE inhibitor administration results in significantly 
decreased plasma concentrations of angiotensin II and decreased plasma aldosterone 
concentrations (and increased concentrations of angiotensin I).  Angiotensin 
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converting enzyme is also responsible for the degradation of bradykinin, a naturally 
occurring vasodilator. 
 There is some evidence to show that ACE-inhibitors are responsible for the inhibition 
of this pathway leading to an accumulation of bradykinin. Bradykinin enhances the 
production of vasodilators, including endothelium derived relaxing factor (EDRF = 
NO = nitrogen monoxide) and prostaglandin (PG) E2 and I2. 
 Recent studies show that bradykinin stimulates epoxyeicosatrienoic acid release. 
Epoxyeicosatrienoic acids are cytochrome P450 epoxygenase metabolites of 
arachidonic acid. They are synthesized by the vascular endothelium and open calcium-
activated potassium channels, hyperpolarize the membrane, and relax vascular smooth 
muscle, resulting in vasodilation, independently of NO and PG production Cutaneous 
vasodilation results in an increased skin temperature and redness. Flushing therefore 
isan adverse reaction, which can be directly related to the pharmacological effect of 
many vasodilator drugs, including calcium antagonists and nitrates. 
Pharmacokinetics 
Absorption   : Approximately 25%, but widely variable between individuals  
                                                    (6 to 60%) in all doses tested (5-80 mg); absorption is            
                                                    Unaffected by food. 
Bioavailability   : 25% 
   Half life   : Effective half life of accumulation following multiple dosing  
                                                       is 12 hours. 
Plasma protein binding                : Lisinopril does not appear to be bound to serum proteins other 
                                                       than ACE. 
Volume of distribution                : 31-36 liter 
Metabolism   : Does not undergo metabolism, excreted unchanged in urine. 
Excretion   : Lisinopril does not undergo metabolism and is excreted  
                                                       unchanged entirely in the urine. 
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Therapeutic indication   : For the treatment of hypertension and symptomatic congestive 
                                                       heart failure. May be used in conjunction with thrombolytic 
                                                       agents, aspirinand/or β-blockers to improve survival in  
                                                       hemodynamically stable individuals following myocardial  
                                                       infarction. May be used to slow theprogression of renal  
                                                      disease in hypertensive patients with diabetes mellitus and  
                                                       microalbuminuria or overt nephropathy. 
Routes and dosage   : For oral dose (tablets): For congestive heart failure:Adults: 2.5  
                                                       to 20 mg once a day.For Hypertension: Adults: 10 to 40 mg  
                                                       Once a day. 
Contraindications and precautions 
The ACE inhibitors are contraindicated in patients with: 
■ Previous angioedema associated with ACE inhibitor therapy 
■ Renal artery stenosis (bilateral or unilateral with a solitary functioning kidney) 
■ Hypersensitivity to ACE inhibitors 
ACE inhibitors should be used with caution in patients with: 
■ Impaired renal function 
■ Aortic valve stenosis or cardiac outflow obstruction 
■ Hypovolemia or dehydration 
■ Hemodialysis with high-flux polyacrylonitrile membranes 
                        ACE inhibitors are ADEC pregnancy category D, and should be avoided in women 
who are likely to become pregnant. In the U.S., ACE inhibitors must be labelled with a      
"blackbox" warning concerning the risk of birth defects when taken during the second and 
third trimester. 
Their use in the first trimester is also associated with a risk of major congenital 
malformations, particularly affecting the cardiovascular and central nervous systems. 
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Potassium supplementation should be used with caution and under medical supervision 
owing to the hyperkalemic effect of ACE inhibitors. 
Adverse effects 
Common adverse drug reactions include: hypotension, cough, hyperkalemia, 
headache, dizziness, fatigue, nausea, and renal impairment. Fein also suggests ACE inhibitors 
might increase inflammation-related pain, perhaps mediated by the buildup of bradykinin that 
accompanies ACE inhibition. 
ACE inhibitors may cause hyperkalemia. Suppression of angiotensin II leads to a 
decrease in aldosterone levels. Since aldosterone is responsible for increasing the excretion of 
potassium, ACE inhibitors can cause retention of potassium. Some people, however, can 
continue to lose potassium while on an ACE inhibitor. 
A severe rare allergic reaction can affect the bowel wall and secondarily cause 
abdominal pain. Some patients develop angioedema due to increased bradykinin levels. There 
appears to be a genetic predisposition toward this adverse effect in patients who degrade 
bradykinin more slowly than average. 
In pregnant women, ACE inhibitors taken during the first trimester have been 
reported to cause major congenital malformations, stillbirths, and neonatal deaths. Commonly 
reported fetal abnormalities include hypotension, renal dysplasia, anuria/oliguria, 
oligohydramnios, intrauterine growth retardation, pulmonary hypoplasia, patent ductus 
arteriosus, and incomplete ossification of the skull.Overall, about half of newborns exposed 
to ACE inhibitors are adversely affected. 
Drug interactions 
1. Amiloride               -   Increased risk of hyperkalemia 
2. Lithium                   - The ACE inhibitor increases serum levels of lithium 
3. Spironolactone        -Increased risk of hyperkalemia 
4. Tizanidine               - Increases the risk of hypotension with the ACE inhibitor 
5. Spironolactone        -Increased risk of hyperkalemia 
6. Tobramycin             -Increased risk of nephrotoxicity 
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Food interaction 
 High salt intake may attenuate the antihypertensive effect of lisinopril. 
 Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium  
Increase the risk of hyperkalemia. 
 Take without regard to meals. 
Combination with other drugs 
Lisinopril + Hydrochlorthiazide 
Lisinopril + Amlodipine 
 
                                                           GLIPIZIDE
63, 64
 
          Chemical structure   : 
 
 
        Chemical name   : 1-cyclohexyl-3-[[4-[2-[[(5-methylpyrazine-2-  
                                                            yl)carbonyl]amino]ethyl]phenyl]sulphonyl]urea 
        Molecular formula  : C21H27N5O4S 
        Molecular weight  : 445.5 
        Description   : A white or almost white, crystalline powder. 
        Solubility   : Practically insoluble in water, very slightly soluble in  
                                                           methylene chloride and in  acetone, practically   
                                                            insoluble inethanol (96 per cent). It dissolves in dilute  
                                                            solutions of alkali hydroxides. 
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         Melting point   : Melts between 208 ̊ C - 209̊ C 
         Loss on drying   : Not more than 0.5 percent, determined on 1g by drying  
                                                            In an  oven at 105 ̊ C. 
         Sulphated ash   : Not more than 0.2 percent. 
Mechanism of action  :  
Glipizide is a second generation sulfonylureas, an oral hypoglycaemic agent for the 
management of non-insulin dependent diabetes mellitus (type II diabetes). Glipizide has a 
more rapid onset of hypoglycaemic effect than Glyburide (Glibenclamide) and a shorter 
duration of action. Glipizide reduces blood glucose by stimulating insulin secretion and 
altering insulin sensitivity. 
Sulfonylureas receptor on the pancreatic beta-cell inhibiting the adenosine 
triphosphate dependent potassium channel (K-ATP). Stabulization of potassium efflux causes 
depolarization and activation of the L-type calcium channel. Influx of calcium stimulates 
insulin secretion. The effect of sulfonylurea is similar to that of glucose at the cellular level; 
however, sulfonylureas only stimulates phase I (initial rapid peak) release of insulin and 
shows no effect on phase II (prolonged insulin release). When sulfonylurea treatment is 
initiated, insulin levels increase and plasma glucose levels gradually decrease. As the glucose 
levels decrease, insulin levels also decrease but still remain higher than pretreatment level. 
Pharmacokinetics 
          Absorption   : Gastrointestinal absorption is uniform, rapid, and  
                                                            Essentially complete.   
Half life   : 2-5 hours 
Plasma protein binding :  98-99%, primarily to albumin. 
Metabolism   : Glipizide is metabolized by cytochrome P450 
                                                   enzymes. 
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Excretion    : The primary metabolites are inactive hydroxylation  
                                                               products and polar conjugates and are excreted mainly  
                                                               in the urine. 
Therapeutic indication  : Indicated as an adjunct to diet and exercise to improve 
                                                                        glycemic control in adults with type 2 diabetes  
                                                                         mellitus. 
Routes and dosage   : Oral routes of administration – 2.5mg, 5mg and 10mg.  
                                                              The maximum recommended daily dose of Glipizide                 
                                                               is 40mg per day. 
Contraindication   : Glipizide is contraindicated in pregnancy, lactation,  
                                                               renal insufficiency, impaired adrenocortical function,  
ketoacidosis. 
Adverse effects   : 
1. Cardiovascular   -  Edema, syncope 
2. Central nervous system  - Anxiety, depression, dizziness, headache, insomnia 
3. Dermatologic   - Rash, urticaria, photosensitivity, pruritus 
4. Endocrine & metabolic  - Hypoglycemia, hyponatremia 
5. Gastrointestinal   - Anorexia, nausea, vomiting, diarrhea 
6. Hematologic   - Hemolytic anemia, bone marrow depression 
7. Hepatic    - Cholestatic jaundice, hepatic porphyria 
8. Neuromuscular& skeletal - Arthralgia, leg cramps, myalgia, tremor 
9. Ocular    - Blurred vision 
10. Renal    - Diuretic effect 
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Drug interactions   :  
Atenolol  - May decrease symptoms of hypoglycemia. 
Rifampin  - May decrease the effect of  Glipizide. 
Chloamphenicol - May increase the effect of Glipizide. 
Clofibrate  - May increase the effect of Glipizide. 
Food Interactions 
1. Avoid alcohol. 
2. Avoid sugar and sugary food. 
3. Take 30-60 minutes before breakfast. 
       Combination with the other drugs 
       Glipizide and Metformin 
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                                 7. EXCIPIENTS PROFILES 
PHARMACEUTICAL EXCIPIENTS 
               Pharmaceutical excipients are substances, other than the pharmacologically active 
drug or prodrug, which are included in the manufacturing process or contained in the finished 
pharmaceutical product dosage form. Excipients provide enhanced functionality to the 
pharmaceuticals, aid the innovations in the drug development and help improve patent life as 
well. Excipients make the products more functional at a lower cost, a benefit much desired by 
the pharmaceutical industry that is inundated with pressures to reduce costs. 
                   Excipients play a wide variety of functional roles in pharmaceutical dosge forms. 
Including, 
 Modulating the solubility and bioavailability of active pharmaceutical ingredients. 
 
 Increasing the stability of active ingredients in dosage forms. 
 
 
 Helping active ingredients maintain preferred polymorphic forms or conformations. 
 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 
 
 Acting as antioxidents, emulsifying agents, aerosol propellants, tablet binders and 
tablet disintegrants. 
 
 Preventing aggregation or dissertation (e.g of protein and polysaccharides actives). 
 
 
 Modulating immunogenic responses of active ingredients (e.g adjunts). 
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                                     SODIUM STARCH GLYCOLATE
65
 
1. Non proprietary names 
                  BP: Sodium Starch Glycolate, PhEur: Sodium Starch Glycolate, USP-NF: Sodium 
Starch Glycolate. 
2. Synonyms 
                 Carboxy methyl starch, sodium salt; carboxy methyl amylum natricum; Explosol:  
Explotab; Glycolys; Primojel; starch methyl ether, sodium salt; Tablo; Vivastar P. 
3. Chemical name 
                Sodium carboxy methyl starch 
4. Functional category  
                Tablet and capsule disintegrant 
5. Description  
                Sodium starch glycolate is a white or almost white free-flowing very hygroscopic 
powder. 
6. Solubility 
                 Practically insoluble in methylene chloride. It gives a translucent susupension in 
water. 
7. Applications 
                 Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either direct-
compression or wet-granulation processes. The usual concentration employed in a 
formulation is between 2% and 8%, with the optimum concentration of about 4%. 
Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling. 
Increasing the tablet compression pressure also appears to have no effect on disintegration 
time. 
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HYDROXYPROPYLMETHYL CELLULOSE
65
 
1. Non proprietary names 
                BP: Hypromellose JP: Hypromellose PhEur: Hypromellose, USP: Hypromellose 
2. Synonyms 
                 Benecel MHPC; E464; hydroxyl propyl methylcellulose; HPMC; 
hydroxylpropylcellulose; Metolose; MHPC; Pharmacoat; Tylopur; Tylose. 
3. Chemical name 
                 Cellulose hydroxyl propyl methyl ether 
4. Molecular weight 
                  Molecular weight is approximately 10000-1500000 
5. Functional category  
                  Bio adhesive material, coating agent, controlled release agent, emulsifying agent, 
film-forming agent, suspending agent, sustained release agent, tablet binder. 
6. Description 
                  Hypromellose is an odourless and tasteless, white or creamy-white fibrous or 
granular powder. 
7. Solubility 
                   Soluble in cold water, forming a viscous colloid solution; practically insoluble in 
hot water, chloroform, ethanol (95%) and ether. 
8. Incompatibilities 
                 Hypromellose is incompatible with some oxidizing agents. 
9. Applications 
                 Hypromellose is widely used in oral, ophthalmic, nasal and topical pharmaceutical 
formulations. It is primarily used as a tablet binder, in film coating and as a matrix for use in 
extended release tablet formulations. Concentrations between 2-5% w/w may be used as a 
binder in either wet or dry granulation processes. High viscosity grades may be used to retard 
the release of drugs from a matrix at levels of 10-80% w/w in tablets and capsules. 
Hypromellose is also used in liquid oral dosage forms as a suspending and thickening agent 
at concentrations ranging from 0.25-5.0%. 
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                                                  ETHYL CELLULOSE
65
 
1. Non proprietary names 
                   BP: Ethyl cellulose, PhEur: Ethyl cellulose, USP-NF: Ethyl cellulose 
2. Synonyms 
                  Aqua coat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosam; Sureleas. 
3. Chemical name 
                 Cellulose ethyl ether 
4. Empirical formula and molecular weight 
                 Ethyl cellulose is partially ethoxylated. Ethyl cellulose with complete ethoxyl 
substitution (DS = 3) is C12H2306 (C12H2205) n C12H2305 where n can vary to provide a wide 
variety of molecular weight. 
5. Functional category 
                  Coating agent, tablet binder, tablet filler, viscosity increasing agent. 
6. Description 
                  Ethyl cellulose is a tasteless, free flowing and white to light tan-colour powder. 
7. Solubility 
                  Ethyl cellulose is practically insoluble in glycerine, propylene glycol and water. 
8. Incompatibilities 
                   Incompatible with paraffin wax and microcrystalline wax. 
9. Applications 
                   Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
The main use of ethyl cellulose in oral formulation is as a hydrophobic coating agent for 
tablets and granules. Ethyl cellulose coatings are used to modify the release of a drug, to 
mask an unpleasant taste, or to improve the stability of a formulation. High viscosity grades 
of ethyl cellulose are used in drug microencapsulation. Ethyl cellulose has also been used as 
an agent for delivering therapeutic agents from oral (e.g. dental) appliances. In topical 
formulations, ethyl cellulose is used as a thickening agent in creams, lotions or gels, provided 
an appropriate solvent is used. Ethyl cellulose is additionally used in cosmetics and food 
products. 
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                                               MAGNESIUM STEARATE
65
 
1. Non proprietarynames 
                  BP: Magnesium stearate, JP: Magnesium stearate, PhEur: Magnesium stearate 
USP-NF: Magnesium stearate. 
2. Synonyms 
                  Dibasic magnesium stearate; magnesium distearate; magnesia stearates; 
magnesium octadecanoic acid, magnesium salt; magnesium salt; Stearic acid, magnesium 
salt; synpro 90. 
3. Chemical name 
                 Octadecanoic acid magnesium salt 
4. Empirical formula 
                 C36H70MgO4 
5. Molecular weight 
                 591.24 
6. Functional category 
                Tablet and capsule lubricant 
7. Description 
                Magnesium stearate is a very fine, light white, impalpable powder of low bulk 
density, having a faint odour of Stearic acid and a characteristic taste. The powder is greasy 
to the touch and readily adheres to the skin. 
8. Incompatibilities 
                 Incompatible with strong acids, alkalis and iron salts. 
9. Applications 
                 Magnesium stearate is widely used in cosmetics, foods and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. Magnesium stearate is hydrophobic and may 
retard the dissolution of a drug from a solid dosage form; the lowest possible concentration is 
therefore used in such formulations. It is also used in barrier creams. 
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                                      MICROCRYSTALLINE CELLULOSE
65
 
1. Non-proprietary names 
               BP: Microcrystalline cellulose, JP: Microcrystalline cellulose, PhEur: cellulose, 
Microcrystalline, USP-NF: Microcrystalline cellulose. 
2. Synonyms 
             Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristallinum; Celphere; 
Ceolus KG; crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; MCC Sanaq; 
Pharmacel; Tabulose; Vivapur. 
3. Chemical name  
            Cellulose 
4. Empirical formula 
            (C6H10O5) n where n = 220 
5. Functional category 
            Tablet and capsule diluents, adsorbent; tablet disintegrant, suspending agent. 
6. Description 
            Microcrystalline cellulose is purified, partially depolymerised cellulose that occurs as 
a white, odourless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grades that have different 
properties and applications. 
7. Solubility 
            Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, 
dilute acids and most organic solvents. 
8. Incompatibilities 
            Microcrystalline cellulose is incompatible with strong oxidizing agents. 
9. Applications 
            Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet granulation 
and direct compression processes. In addition to its use as binder/diluents, microcrystalline 
cellulose also has some lubricant and disintegrant properties that make it useful in tableting. 
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                                                              POVIDONE
65
 
1. Non-proprietary names 
               Povidone 
2. Synonyms 
               E1201; Kollidon; Plasdone; poly [1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylyrrolidone; povidonum; povipharm; PVP; 1-vinyl-2-pyrrolidinone polymer. 
3.Chemical name 
               1-Ethyneyl-2-pyrrolidinone homopolymer 
4. Empirical formula 
               (C6H9NO) n 
5. Molecular weight  
                2500-3,000,000 
6. Functional category 
                 Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
7. Description 
                 Povidone occurs as a fine, white to creamy-white coloured, odourless or almost 
odourless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates. 
8. Solubility 
                Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water. 
Practically insoluble in ether, hydrocarbons and mineral oil. 
9. Applications 
                Povidone is used in variety of pharmaceutical formulations primarily used in solid 
dosage forms. In tableting, povidone solutions are used as binders in wet granulation 
processes. It is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol or hydroalcoholic solutions. Povidone is used as a solubilizers in 
oral and parenteral formulations and has been shown to enhance dissolution of poorly soluble 
drugs from solid dosage forms. Povidone is also used as a suspending, stabilizing, or 
viscosity increasing agent in a number of topical and oral suspensions and solutions. 
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                                             ISOPROPYL ALCOHOL
65
 
1. Non proprietary names 
            BP: Isopropyl Alcohol, JP: Isopropanol, PhEur: Isopropyl Alcohol, USP: Isopropyl 
Alcohols 
2. Synonyms 
            Alcohol isopopylicus; dimethyl carbinol; IPA; Isopropanol; petrohol; 2-propanol; sec-
propyl alcohol; rubbing alcohol. 
3. Chemical name  
            Propan-2-ol 
4. Empirical formula 
            C3H8O 
5. Molecular weight 
             60.1 
6. Functional category 
             Disinfectant; solvent 
7. Description  
             Isopropyl alcohol is a clear, colourless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odour resembling that of a mixture of ethanol and acetone; it has a 
slightly bitter taste. 
8. Solubility 
             Miscible with benzene, chloroform, ethanol (95%), ether, glycerine, and water. 
9. Incompatibilities 
            Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which 
cause decomposition. 
10. Applications 
             Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations. Primarily as a solvent in topical formulations. Although it is used in lotions, the 
marked degreasing properties of isopropyl alcohol may limit its usefulness in preparations 
used repeatedly. Isopropyl alcohol is also used as a solvent both for tablet film coating and 
for tablet granulation, where the isopropyl alcohol is subsequently removed by evaporation. 
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8. MATERIALS AND METHODS 
Table 1: List of materials and their applications in formulation 
S.NO NAME OF THE 
MATERIAL 
MANUFACTURE/SUPPLIER USE IN 
FORMULATION 
 
1 
 
Lisinopril 
 
Unimark remedies ltd, Chennai. 
 
Active ingredient 
 
2 
 
Glipizide 
 
Unimark remedies ltd, Chennai. 
 
Active ingredient 
 
3 
 
HPMC K100M 
 
Samsung fine chemicals 
 
Hydrophilic polymer 
 
4 
 
Ethyl cellulose 
 
A to Z pharmaceuticals, 
Chennai. 
 
Hydrophobic polymer 
 
5 
 
Sodium starch glycolate 
 
S.D. fine chemicals, Mumbai. 
 
Super disintegrant 
 
6 
 
Polyvinyl pyrrolidone  
K 30 
 
S.D. fine chemicals, Mumbai. 
 
Binder 
 
7 
 
Magnesium stearate 
 
S.D. fine chemicals, Mumbai. 
 
Lubricant 
 
8 
 
Talc 
 
 
S.D. fine chemicals, Mumbai. 
 
Glidant 
 
9 
 
Microcrystalline 
cellulose 
 
 
Vikaas chemicals, Chennai. 
 
Diluent 
 
 
10 
 
 
Isopropyl alcohol 
 
Supra chemicals, Chennai. 
 
Solvent 
 
11 
 
Lake poncea 4R 
 
Zudila Enterprises, China. 
 
Colouring agent 
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                                    Table 2: List of instruments/equipments 
S.NO Equipments / Instruments Manufacture/Supplier 
1 Electronic weighing balance Shimadzu, Japan. 
2 Hot air oven Industrial heaters, Chennai. 
3 10 station compression machine Rimek, India. 
4 Digital vernier calliper Mitutoyo, Japan. 
5 Monsanto hardness tester 
 
Erweka, Mumbai. 
6 Friabilator 
 
Roche, India. 
7 pH meter 
 
Symchrony, India. 
8 Sonicator 
 
.Leela electronics, Chennai. 
9 Disintegrstion apparatus 
 
Veego, Mumbai. 
10 Dissolution apparatus 
 
Veego, Mumbai 
11 UV – Visible Spectrophotometer 
 
Shimadzu, Japan. 
12 Fourier Transform Infra Red 
Spectrophotometer 
Nicolet, India. 
13 Stability chamber 
 
Technico, India. 
14 Moisture analysis 
 
Sartorius, German. 
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METHODOLOGY 
   1. PREFORMULATION STUDIES
66
 
                  Pre-formulation  study  is  the  process  of  optimizing  the delivery  of  drug 
through determination of physicochemical properties of the new compound that could affect  
drug  performance  and  development  of  an  efficacious,  stable and  safe  dosage form.  It 
is  the  first  step  in  rational  development  of drug dosage  forms  of  a  drug substance. It 
provides the information required to define the nature of the drug and a frame work for the 
drug combination with pharmaceutical excipients in dosage form. 
   A. Organoleptic properties 
          The colour, odour and taste of the drugs were studied. 
   B. Particle size and shape 
          Particle size and shape of the drugs were studied by optical microscopic method. 
    C. Melting point 
          Melting points of the drugs were confirmed by capillary tube method. 
     D. Solubility analysis 
Solubility is the important parameter for preformulation studies because, 
1. It affects the dissolution of the drug. 
2. Bioaviability of drug is directly affected by oral administration and also by dissolution. 
3. Particle size, shape, surface area may affect the dissolution characteristics of drug 
hence it should be determined during preformulation. 
Method : Weighed quanditity of drug was added to the suitable volume of solvent and 
solubility checked. 
   E. Loss on drying (%) 
               1g of drug was accurately weighed and dried in an oven at 105 ̊ C for 3 hours. By 
gentle sidewise shaking, the sample was distributed at the specified temperature for 
constant weight. The drug sample was allowed to come to room temperature in a 
desiccators before weighing. 
The difference between successive weights should not be more than 0.5mg 
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The loss on drying is calculated by the formula: 
                                                             W3 – W2 
                                         % LOD = ____________X100 
                                                              W2 – W1 
Where,  
W1 – Weight of empty weighing bottle 
W2 – Weight of weighing bottle + sample 
W3 – Weight of weighing bottle + dried sample 
 
DRUG EXCIPIENT COMPATIBILTY STUDY 
               The drug and the excipients chosen for the formulations were screened for 
compatibility by physical methods and Fourier Transform Infrared spectroscopic studies. 
 
Physical compatibility study
66
 
              The physical compatibility studies were conducted to provide valuable 
information to the formulator in selecting the appropriate excipients for the formulation. It 
was done by mixing the drugs and the excipients and kept at room temperature and at 40 ̊ C 
and 75% RH. Any change in colour of the physical mixture was observed visually. 
 
Chemical compatibility study by FTIR
67
 
              Infrared spectroscopy can be used to identify a compound and also to investigate 
the composition of the mixture. Pure drugs, polymers, excipients, drug excipient mixture 
was subjected to FTIR studies to investigate the drug- excipient interactions. The IR 
spectra of the test samples were obtained by pressed pellet technique using potassium 
bromide. 
 
PREPARATION OF BUFFER SOLUTIONS
4
 
Preparation of 0.1M (pH 1.2) Hydrochloric acid 
             8.5ml of the hydrochloric acid was taken, dissolved in water and made upto 
1000ml to get 0.1M hydrochloric acid. 
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Preparation of pH 6.8 phosphate buffer solution 
               Take 50ml of 0.2M potassium dihydrogen phosphate in a 200ml volumetric flask 
and add 22.4ml of 0.2 M sodium hydroxide solution, then the volume was made upto 
200ml using distilled water. 
Preparation of 0.2M potassium dihydrogen phosphate 
              27.218 g of potassium dihydrogen phosphate was dissolved in distilled water and 
the volume was made upto 1000ml using distilled water. 
Preparation of 0.2 M Sodium hydroxide 
               8g of sodium hydroxide was dissolved in distilled water and made upto 1000ml 
with distilled water. 
 
CALIBRATION CURVE 
For Lisinopril
34
 
                100mg of drug was weighed and transferred to a 100ml standard flask and made 
upto volume using 0.1M HCl. 10ml of the stock solution was pipetted out into separate 
100ml standard flask and made upto the volume using 0.1M HCl. From the resulting 
solution 2, 4, 6, 8 and 10 ml were pipette out into five separate 100ml standard flasks and 
made upto volume using 0.1M HCl to represent 2, 4, 6, 8 and 10 µg/ml of the drug. The 
absorbance of the solutions was measured at 207nm taking 0.1M HCl as blank using UV – 
Visible spectrophotometer. The calibration curve was then plotted taking concentration 
(µg/ml) along X-axis and absorbance along Y- axis. 
For Glipizide
47
 
                100mg of drug was weighed and transferred to a 100ml standard flask and made 
upto volume using pH 6.8 phosphate buffer. 10ml of the stock solution was pipetted out 
into separate 100ml standard flask and made upto the volume using pH 6.8 phosphate 
buffer.  From the resulting solution 2, 4, 6, 8 and 10 ml were pipette out into five separate 
100ml standard flasks and made upto volume using pH 6.8 phosphate buffer to represent 2, 
4, 6, 8 and 10 µg/ml of the drug. The absorbance of the solutions was measured at 207nm 
taking pH 6.8 phosphate buffer as blank using UV – Visible spectrophotometer. The 
calibration curve was then plotted taking concentration (µg/ml) along X-axis and 
absorbance along Y- axis. 
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PRECOMPRESSION STUDIES OF DRUG AND BLEND 
FLOW PROPETY MEASUREMENTS
66
 
                The flow properties of powders are critical for an efficient tabletting operation. A 
good flow of the powder or granulation to be compressed is necessary to assure efficient 
mixing and acceptable weight uniformity for the compressed tablets. The flow property 
measurements include bulk density, tapped density, compressibility index, Hausner’s ratio 
and angle of repose. The flow property measurements of drug and blend were determined 
to select the type of granulation technique to be carried out for the formulation. 
A. BULK DENSITY71 
               It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder and initial weight was 
noted. This initial volume was called the bulk volume. From this the bulk density was 
calculated according to the formula mentioned below. It is expessed in g/ml and is given 
by  
                                          ρb = M / Vb 
      where, M and Vbare mass of powder and bulk volume of the powder respectively. 
B. TAPPED DENSITY (ρt )
71
 
               It is the ratio of weight of the powder to the tapped volume of powder. The 
powder was introduced into a measuring cylinder with the aid of funnel and tapped for 500 
times on a wooden surface at a 2 sec interval and the volume attained is the tapped 
volume. It is expressed in g/ml and is given by 
                                             ρt  = M / Vt 
where, M and Vtare mass of powder and tapped volume of the powder respectively. 
C. ANGLE OF REPOSE71 
                The flow properties were characterized in terms of angle of repose, carr’s index 
and Hausner’s ratio. For determination of angle of repose (θ), the drug and the blend were 
poured through the walls of a funnel, which was fixed at a position such that its lower tip 
was at a height of exactly 2.0cm above hard surface.  
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                 The drug or the blends were poured till the time when upper tip of the pile 
surface touched the lower tip of the funnel. Angle of repose was calculated using 
following equation. 
                                   Θ = tan-1 (h/r) 
Where, h= height of the pile in cm; r = radius of the pile in cm. 
 
D. CARR’S INDEX OR  % COMPRESSIBILITY71 
               It indicates powder flow properties. It is measured for determining the relative 
importance of interparticulate interactions. It is expressed in percentage and is given by, 
 
                                                  ρt -ρb 
                                            CI = 
__________
X 100 
                                                      ρt 
where, ρt and ρb are tapped density and bulk density respectively. 
E. HAUSNER’S RATIO71 
                    Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula. 
 
                                         HR = ρt / ρb 
Where, ρtand ρbare tapped density and bulk density respectively. 
TABLE 3: VALUES OF ANGLE OF REPOSE, COMPRESSIBILITY INDEX AND 
HAUSNER’S RATIO69 
Flow property Angle of Repose 
(θ) 
Compressibilty 
Index 
Hausner’s Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >65 >38 >1.60 
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                                            9. FORMULATION DEVELOPMENT 
 
Formulation of Immediate release granules of Lisinopril
9
 
                Lisinopril belongs to class III drug in BCS classification i.e. high solubility and low 
permeability. But it has half life period 12 hours. To improve the onset of action the 
immediate granules of Lisinopril were prepared by wet granulation technique. Sodium starch 
glycolate (SSG) was used as a super disintegrant in 4%, 6% and 8% concentrations to 
improve the dissolution of the drug. The granules were compressed by 10 station 
compression machine. 
 
                              Table 4: Composition of immediate release granules 
 
S.NO Ingredients L-1(mg) L-2(mg) L-3(mg) 
1 Lisinopril 10 10 10 
2 Sodium starch glycolate 8 12 16 
3 Polyvinyl pyrrolidone K-30 8 8 8 
4 Magnesium stearate 4 4 4 
5 Talc 2 2 2 
6 Microcrystalline cellulose 175 173 169 
7 Lake ponceau 4R 1 1 1 
8 Isopropyl alcohol q.s q.s q.s 
Total weight 200 200 200 
 
 
                  The immediate release tablet of Lisinopril was formulated and optimized. The 
optimized formulation was used for the final bilayer tablets. 
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Flow chart for formulation of Lisinopril immediate release (IR) tablets 
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FORMULATION OF GLIPIZIDE SUSTAINED RELEASE TABLETS 
 The sustained release granules were prepared by wet granulation technique. Different 
polymers such as HPMC K 100 M and Ethyl cellulose were used in different ratios. The tablets 
were compressed by 10 station compression machine using mm punches. The optimized batch of 
sustained release tablets of Glipizide was then compressed with the optimized batch of 
immediate release Lisinopril tablets to get bilayer tablets. 
                               Table 5: Composition of sustained release granules 
S.NO Ingredients G-1(mg) G-2(mg) G-3(mg) G-4(mg) G-5(mg) 
1 Glipizide 10 10 10 10 10 
2 HPMC K100 M - 50 25 50 75 
3 Ethyl cellulose 50 - 25 25 25 
4 Polyvinyl pyrrolidone 12.5 12.5 12.5 12.5 12.5 
5 Magnesium stearate 10 10 10 10 10 
6 Talc 2.5 2.5 2.5 2.5 2.5 
7 Microcrystalline cellulose 165 165 165 140 115 
8 Isopropyl alcohol q.s q.s q.s q.s q.s 
Total weight 250 250 250 250 250 
 
The sustained release tablet of Glipizide was formulated and optimized. The optimized 
formulation was used for the final bilayer tablets. 
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Flow chart for sustained release tablets (SR) of Glipizide 
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Flow chart for bilayer tablets of Lisinopril(IR) and Glipizide(SR) 
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1. POST COMPRESSION STUDIES 
A. PHYSICAL PARAMETERS 
1. General appearance 
The general appearance of the tablets from each formulation batch was observed. The general 
appearance parameters such as shape, colour, presence or absence of odour and taste were 
evaluated visually. 
 
2. Uniformity of weight4 
              Twenty tablets were randomly selected from each batch and individually weighed. 
The average weight and standard deviation of 20 tablets was calculated. The batch passes  the  
test  for  weight variation, if not more than two of  the individual weight deviates from the 
average weight by more than the percentage shown in the Table and  none  should  deviate  by  
more  than  twice  the  percentage  shown.  The average weight and standard deviation of the 
tablets of each batch were given in the table. 
 
                                Table 6: IP limit for uniformity of weight 
Average weight of tablet Percentage deviation 
80 or less 10 
80 to 250 7.5 
More than 250 5 
 
3. Thickness and diameter4 
                  The  control  of  physical  dimension  of  the  tablet  such  as  thickness and 
diameter are  essential  for consumer  acceptance  and  to  maintain  uniformity  of  tablet  
weight. Six tablets were selected from each batch and their thickness and diameter were 
measured by using vernier callipers.  The  average  thickness  and  diameter  with  standard  
deviation  of  the  tablets from each batch were calculated and tabulated. 
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4. Hardness4 
               The  tablet  crushing  load  is  the  force  required  to  break  a  tablet  by  
compression. Hardness was measured by using hardness tester. For each batch, six tablets 
were selected randomly and evaluated. Hardness of about4-6 kg/cm 
2
 is considered to be 
minimum for uncoated tablets and for mechanical stability. 
 
5. Friability4 
                  Friability test is performed to assess the effect of friction and shocks, which may 
often cause tablet to chip, cap or break. Roche friabilator was used for this purpose. Preweighed  
sample  of  twenty tablets  were  placed  in  the  friabilator,  which  was  then operated  for  100  
revolutions.  After 100 revolutions the tablets were dusted and reweighed. Compressed tablets 
should not lose more than 1% of their weight. 
 
              % Friability= Initial Weight–Final Weight/ Final Weight X 100 
 
6. Disintegration4 
                Randomly  six  tablets  were  selected  from  each  batch  for  disintegration  test. 
Disintegration test was performed without disc in simulated gastric fluid (37 ± 0.5 °C) using 
United States Pharmacopeia (USP) disintegration apparatus. The mean standard deviations 
(SD) of six tablets were calculated. 
 
    B. DRUG CONTENT 
     1. FOR IR TABLETS CONTAINING LISINOPRIL
34
 
                 Twenty tablets were selected randomly, weighed and finely grounded. An 
accurately weighed quantity of powder equivalent to 10mg of Lisinopril was transferred to a 
100ml volumetric flask and dissolved. The volume was made upto the mark with 0.1M HCl. 
From this solution 10ml was taken and further diluted with 0.1M HCl in a 100ml volumetric 
flask. The absorbance of the resulting solution was measured at 207nm taking 0.1M HCl as 
blank using UV-Visible spectrophotometer. The concentration was obtained from the 
calibration graph. 
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2. FOR SR TABLETS CONTAINING GLIPIZIDE
47
 
                 Twenty tablets were selected randomly, weighed and finely grounded. An 
accurately weighed quantity of powder equivalent to 50mg of Glipizide was transferred to a 
100ml volumetric flask and dissolved in 5ml of 0.1N NaOH and the volume was made upto 
the mark with pH 6.8 phosphate buffer. From this solution 10ml was taken and further diluted 
with pH 6.8 phosphate buffer  in a 100ml volumetric flask. From this solution 5ml was taken 
and diluted with pH 6.8 phosphate buffer in 50ml volumetric flask. The absorbance of the 
resulting solution was measured at 276nm taking pH 6.8 phosphate buffer as blank using UV-
Visible spectrophotometer. The concentration was obtained from the calibration graph. 
C. BILAYER TABLETS OF LISINOPRIL AND GLIPIZIDE (SIMULTANEOUS 
EQUATION METHOD)
72
 
Simultaneous estimation of Lisinopril and Glipizide was carried out using UV-Visible 
spectrophotometer. 
     PROCEDURE
70
 
     The following equations were used to determine the contents. 
                                                  A2ay1 – A1ay2 
                          Cx =         _________________ 
                                                 ax2 ay1 – ax1ay2 
 
                                                 A1ax1 – A2ax1 
                          Cy =         _________________ 
                                                 ax2 ay1 – ax1ay2 
 
where,  ax1and ax2 =  The absorptivity of drug X at λ1 and λ2 respectively. 
ay1and ay2 = The absorptivity of drug Y at λ1 and λ2 respectively. 
 A1and A2=  The absorbance of sample at λ1 and λ2 respectively. 
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                                     (A1/A2) /(ax1/ax2) and (ay1/ay2) / (A1/A2) 
The ratios should lie outside the range of 0.1 – 2.0 for the precise determination of X and Y 
drugs. This criteria is satisfied only when the λmax of the two components is reasonably dissimilar 
and the components should not interact chemically. 
1. Preparation of standard stock solution of Lisinopril
9
 
                  Lisinopril equivalent to 100mg was accurately weighed and dissolved. The volume 
was made upto mark with pH 6.8phospahte buffer in 100ml standard flask. From this solution 
10ml was taken and diluted with pH 6.8phospahte buffer in 100ml volumetric flask. From this 
solution 10ml was taken and further diluted with pH 6.8phospahte buffer in 100ml standard flak. 
2. Preparation of standard stock solution of Glipizide
47
 
                  Glipizide equivalent to 100mg was accurately weighed and dissolved. The volume 
was made upto mark with pH 6.8phospahte buffer in 100ml standard flask. From this solution 
10ml was taken and diluted with pH 6.8phospahte buffer in 100ml volumetric flask. From this 
solution 10ml was taken and further diluted with pH 6.8phospahte buffer in 100ml standard flak. 
3. Preparation of sample solution 
                 Twenty tablets were selected randomly, weighed and finely grounded. An accurately 
weighed quantity of powder equivalent to 100mg of Glipizide was transferred to a 100ml 
volumetric flask and dissolved in 5ml of 0.1N NaOH and the volume was made upto the mark 
with pH 6.8 phosphate buffer. From this solution 10ml was taken and further diluted with pH 6.8 
phosphate buffer in a 100ml volumetric flask. From this solution 10ml was taken and further 
diluted with pH 6.8 phosphate buffer in a 100ml volumetric flask. The absorbance of resulting 
solution was measured at 207nm and 276nm respectively. The amounts of both the drugs were 
determined. 
D. IN VITRO DISINTEGRATION STUDIES FOR IR TABLETS 
               The disintegration time was determined using disintegration test apparatus. The tablets 
were placed in each of the six tubes of the basket. The assembly was suspended in 0.1M HCl 
maintained at a temperature of 37 ̊ C ± 2̊ C and the apparatus was switched on. The time taken to 
disintegrate the tablets completely was noted. 
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E. IN VITRO DISSOLUTION STUDIES
42
 
1. For IR tablets 
               The release of Lisinopril was determined using Type II (paddle) dissolution apparatus 
under sink condition. 900ml of 0.1M HCl was used as dissolution medium at a temperature of 37 ̊ 
C ± 0.5 ̊ C. The paddle was stirred at a speed of 50 rpm. The release studies were carried out for 
30mins. The absorbance of the solution was measured at 207nm taking 0.1M HCl as blank using 
UV-Visible spectrophotometer. 
2. For SR tablets 
                The release of Glipizide was determined using Type II (paddle) dissolution apparatus 
under sink condition. 900ml of pH 6.8 phosphate buffer was used as dissolution medium at a 
temperature of 37 ̊ C ± 0.5 ̊ C. The paddle was stirred at a speed of 50 rpm. The release studies 
were carried out for 24hours. The absorbance of the solution was measured at 276nm taking pH 
6.8 phosphate buffer as blank using UV-Visible spectrophotometer. 
3. For bilayer tablets 
                The release of bilayer tablet was determined using Type II (paddle) dissolution 
apparatus under sink condition. 900ml of 0.1M HCl was used as dissolution medium for first two 
hours followed by pH 6.8 phosphate buffer solution for next eight hours maintained at a 
temperature of 37 ̊ C ± 0.5 ̊ C. The paddle was stirred at a speed of 50 rpm. The release studies 
were carried out for ten hours. The absorbance of the solution was measured at 207nm and 
276nm taking respective buffer solutions as blank using UV-Visible spectrophotometer and the 
calculations were done by simultaneous equation method. 
F. EVALUATION OF IN VITRO RELEASE KINETICS
73, 74
 
               To study the in vitro release kinetics of the optimized bilayer tablets, data obtained 
from in vitro dissolution study were plotted in various kinetic models. 
1. Zero order equation  
           Zero  order  equation  assumes  that  the  cumulative  amount  of  drug  release  is  
directly related to time. The equation maybe as follows: 
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                                                      C=k0t 
Where, K0 is the zero order rate constant expressed in unit concentration/time and the time in 
hour. A graph of concentration vs time would yield a straight line with a slope equal toK0 and 
intercept the origin of the axis. 
2. First order equation 
               The release behaviour of first order equation is expressed as log cumulative percentage 
of drug remaining vs time. The equation may be as follows. 
                             Log C= Log C0 –kt/2.303 
 
Where C = The amount of drug un-dissolved at t time, C0= Drug concentration at t = 0, k= 
Corresponding release rate constant. 
3. Higuchi kinetics 
              The  Higuchi  release  model  describes  the  cumulative  percentage  of  drug  release vs 
square root of time. The equation may be as follows 
 
                                                           Q = K√t 
 
Where,  Q  =  the  amount  of  drug  dissolved  at  time  t.  K is  the  constant  reflecting  the 
design  variables  of  the  system.  Hence, drug  release  rate  is  proportional  to  the reciprocal of 
the square root of time. 
4. Hixson and crowell erosion equation 
                To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson and Crowell erosion equation. The graph was 
plotted by cube root of % drug remaining Vs Time in hours. 
 
                              Q0
1/3– Qt 
1/3
 = KHC X t 
 
Where, Qt – amount of drug released at time t, Q0 – initial amount of drug, KHC– rate constant for 
Hixson Crowell equation. 
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5. Korsmeyer – Peppas equation 
               Korsmeyer et al developed a simple, semi-empirical model relating exponentially the 
drug release to the elapsed time. The equation may be as follows: 
                                                         Q/Q0= Kt
n
 
Where, Q/Q0= The fraction of drug released at time t, k = Constant comprising the structural  
geometric  characteristics,  n  =  The  diffusion  exponent  that  depends  on  the release 
mechanism. 
   Table 7: Diffusion exponent and solute release mechanism for cylindrical shape 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n > 0.89 Super case II transport 
 
 
G. STABILITY STUDY 
                  Stability studies of optimized bilayer tablets were carried out according to ICH 
guidelines. All the tablets were packed in blisters and kept in a humidity chamber at 40 ± 2 ̊ C 
and 75 ± 5% RH for 3 months. Samples were withdrawn at monthly intervals and analyzed for 
physical characteristics, hardness and in vitro dissolution.  
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                                                 10. RESULTS AND DISCUSSION 
 
                The present work was aimed to formulate bilayer tablets of immediate release 
Lisinopril and sustained release Glipizide. The therapy with these drugs offers a good quality of 
life for patients who are suffering from hypertension and type II diabetes mellitus. 
PREFORMULATION STUDIES 
DRUG CHARACTERIZATION 
LISINOPRIL 
                 Lisinopril raw material obtained from Unimark remedies limited was tested as per in 
house specification and the results are listed. The drug source is identified and found complying 
with the specifications. 
Table 8: Identification of Lisinopril 
S.NO TEST SPECIFICATION RESULTS 
1 Description  A white crystalline powder A white crystalline powder 
2 Loss on drying Maximum 0.4% W/W 0.23% W/W 
3 Solubility  Soluble in water, very slightly  
soluble in ethanol (95%) 
complies  
4 Melting point 146̊ C - 148 ̊ C 145 ̊ C - 149 ̊ C 
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GLIPIZIDE 
                 Glipizide raw material obtained from Unimark remedies limited was tested as per in 
house specifications and the results are listed. The drug source is identified and found complying 
with the specifications. 
Table 9: Identification of Glipizide 
S.NO TEST SPECIFICATION RESULTS 
1 Description A white or almost white, 
crystalline powder 
A white crystalline powder 
2 Loss on drying Not more than 0.5% W/W 0.26% W/W 
3 Solubility Practically insoluble in water, 
very slightly soluble in 
methylene chloride & in  acetone. 
Practically insoluble in ethanol(96%). 
It dissolves in dilute solutions of 
alkali hydroxides. 
Complies 
4 Melting point 208̊ C- 209̊ C 207 ̊ C -208̊ C 
 
DRUG EXCIPIENT COMPATIBILITY STUDY 
Physical compatibility study 
               The compatibility studies were carried out to study the possible interactions between 
active ingredients (Lisinopril & Glipizide) and inactive ingredients. Physical mixtures of both 
API and excipients were prepared separately as per the ratios mentioned in table below and kept 
for stability at 40 ̊ C and 75% RH for one month. Samples were taken out after every 10days and 
were subjected to physical and chemical compatibility tests. The physical compatibility of drug 
and excipients are given. 
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Table 10:  Physical compatibility study drugs and excipients 
S.NO Drug + excipient Description and condition comments 
 
Initial 
Room temperature and  
40̊ C / 75% RH in days 
10th 20th 30th 
1 Lisinopril A white crystalline 
powder 
NC NC NC Compatible  
2 Glipizide  White or almost white 
crystalline powder 
NC NC NC Compatible 
3 Lisinopril 
+Glipizide 
White crystalline  
powder 
NC NC NC Compatible 
4 Sodium starch 
glycolate 
White or almost white  
powder 
NC NC NC Compatible 
5 Magnesium  
stearate 
Light white powder NC NC NC Compatible 
6 Polyvinyl 
pyrrolidone 
White to creamy white 
powder 
NC NC NC Compatible 
7 Talc  White to greyish white 
powder 
NC NC NC Compatible 
8 HPMC K 100M White or creamy white 
powder 
NC NC NC Compatible 
9 Ethylcellulose A white colour powder NC NC NC Compatible 
10 
 
Microcrystalline  
cellulose 
A white crystalline 
powder 
NC NC NC Compatible 
11 Lisinopril 
+SSG 
White or almost white 
powder 
NC NC NC Compatible 
12 Lisinopril 
+magnesium stearate 
White powder NC NC NC Compatible 
13 Lisinopril 
+MCC 
A white crystalline 
powder 
NC NC NC Compatible 
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14 Lisinopril 
+PVP K30 
Creamy white powder NC NC NC Compatible 
15 Glipizide +  
HPMC K100M 
White to creamy white 
powder 
NC NC NC Compatible 
16 Glipizide+ 
EC 
Free flowing white 
coloured powder 
NC NC NC Compatible 
17 Glipizide+ 
PVP K30 
White to creamy white 
Hygroscopic powder  
NC NC NC Compatible 
18 Glipizide+ 
Magnesium stearate 
White crystalline 
Powder 
NC NC NC Compatible 
19 Glipizide + 
MCC 
White or white  
crystalline powder 
NC NC NC Compatible 
20 Lake ponceau  
4R 
Red coloured soft  
powder 
NC NC NC Compatible 
21 Lisinopril+ 
Lake ponceau  
4R 
White to light red 
cloued powder 
NC NC NC Compatible 
22 Lisinopril+ 
Talc 
White to ceamy white 
powder 
NC NC NC Compatible 
23 Glipizide+ 
Talc 
White to ceamy white 
powder 
NC NC NC Compatible 
 
NC – No change 
                The physical compatibility study was performed visually. The study implies that the 
drug and the excipients were physically compatible with each other as there was no change of 
physical parameters. The excipients which are compatible with the drug were selected for the 
formulation. 
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Chemical compatibility study 
                All the samples were scanned at the wave number region of 4000-400 cm
-1
using KBr 
disc method. This KBr discs were formed by taking drug and KBr in a ratio of 1: 100 
respectively. Then this mixture was mixed well in mortar for three to five minutes. A very small 
amount of this mixture was uniformly spread and sandwiched between the pellets and pressed 
using KBr pellet press at a pressure of 20,000 psi for 1min.The pressure was then released and 
pellet was placed into the pellet holder and thus scanned in the IR region. 
Fig 14: FTIR of Lisinopril 
                                     Table 11:IR Spectral Interpretation of Lisinopril 
S.NO Functional group Observed peak 
1 O-H (Carboxylic acid) stretching 3340 cm
-1
 
2 N-H (Primary amine) stretching 3340 cm
-1
 
3 C=O (Carboxylic acid) stretching 1658 cm
-1
 
4 N-H (secondary amine) stretching 3294 cm
-1
 
5 C-H (alkane) stretching 2923 cm
-1
 
6 C-H (Aromatic) stretching 3101cm
-1
 
7 C=N  1658 cm
-1
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                                                           Fig 15: FTIR of Glipizide 
 
                                      Table 12: IR Spectral Interpretation of Glipizide 
S.NO Functional group Observed peak 
1 N-H (Primary amine) stretching 3247 cm
-1
 
2 C=O (Carboxylic acid) stretching 1689 cm
-1
 
3 C-H (alkane) stretching 2854 cm
-1
 
4 C-H (Aromatic) stretching 3116 cm
-1
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                                             Fig 16: FTIR of Lisinopril and Glipizide 
                         Table 13: IR Spectral Interpretation of Lisinopril and Glipizide 
S.NO Functional group Observed peak 
1 O-H (Carboxylic acid) stretching 3325 cm
-1
 
2 C=O (Carboxylic acid) stretching 1689 cm
-1
 
3 N-H (secondary amine) stretching 3247 cm
-1
 
4 C-H (alkane) stretching 2854 cm
-1
 
5 C-H (Aromatic) stretching 3101cm
-1
 
6 C=N  1650 cm
-1
 
 
INFERENCE 
                No shift and no disappearance of characteristic peaks suggesting that there is no 
interaction between the drugs and also with the excipients in the final formulation. 
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                             Fig 17: FTIR of Lisinopril and sodium starch glycolate 
             Table14: IR Spectral Interpretation of Lisinopril and sodium starch glycolate 
S.NO Functional group Observed peak 
1 O-H (Carboxylic acid) stretching 3340 cm
-1
 
2 N-H (secondary amine) stretching 3294 cm
-1
 
3 C-H (alkane) stretching 2923 cm
-1
 
4 C-H (Aromatic) stretching 3101cm
-1
 
5 C=N  1658 cm
-1
 
 
INFERENCE 
                 No shift and no disappearance of characteristic peaks suggesting that there is no 
interaction between the drugs and also with the excipients in the final formulation. 
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                                         Fig 18: FTIR of Glipizide and Ethyl cellulose 
                    Table 15: IR Spectral Interpretation of Glipizide and Ethyl cellulose 
S.NO Functional group Observed peak 
1 N-H (Primary amine) stretching 3325 cm
-1
 
2 C=O (Carboxylic acid) stretching 1689 cm
-1
 
3 C-H (alkane) stretching 2854 cm
-1
 
 
INFERENCE 
                 No shift and no disappearance of characteristic peaks suggesting that there is no 
interaction between the drugs and also with the excipients in the final formulation. 
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                                    Fig 19: FTIR of Glipizide and HPMC K 100 M 
                   Table 16: IR Spectral Interpretation of Glipizide and HPMC K 100 M 
S.NO Functional group Observed peak 
1 O-H (Carboxylic acid) stretching 3325 cm
-1
 
2 C=O (Carboxylic acid) stretching 1650 cm
-1
 
3 C-H (alkane) stretching 2916 cm
-1
 
4 C=N  1689 cm
-1
 
 
INFERENCE 
               No shift and no disappearance of characteristic peaks suggesting that there is no 
interaction between the drugs and also with the excipients in the final formulation. 
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                                       Fig 20: FTIR of optimized bilayer formulation 
                    Table 17:  IR Spectral Interpretation of optimized bilayer formulation 
S.NO Functional group Observed peak 
1 O-H (Carboxylic acid) stretching 3325 cm
-1
 
2 C=O (Carboxylic acid) stretching 1650 cm
-1
 
3 N-H (secondary amine) stretching 3255 cm
-1
 
4 C-H (alkane) stretching 2916 cm
-1
 
5 C=N  1689 cm
-1
 
 
INFERENCE 
                 No shift and no disappearance of characteristic peaks suggesting that there is no 
interaction between the drugs and also with the excipients in the final formulation. 
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1. CALIBRATION CURVE FOR LISINOPRIL 
            The data for calibration curve of Lisinopril in 0.1M HCl is shown in table 21 and 
calibration curve shown in Fig 18. 
                     Table 21: Data for calibration curve of Lisinopril in 0.1M HCl 
S.NO Concentration (µg/ml) Absorbance at λ207nm 
1 0 0 
2 5 0.179 
3 10 0.354 
4 15 0.517 
5 20 0.710 
6 25 0.854 
 
                                          Fig 18: Calibration Curve of Lisinopril 
 
 
               It was found that the solution of Lisinopril in 0.1M HCl show linearity (R
2
 = 0.999) at 
concentrations of 5-25 (µg/ml) and obey Beer Lambert Law. 
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2. CALIBRATION CURVE FOR GLIPIZIDE 
               The data for calibration curves of Glipizide in pH 6.8 phosphate buffer is shown in 
table 22 and the calibration curve shown in Fig 19. 
                       Table 22: Data for calibration curve of Glipizide in pH 6.8 buffer 
S.NO  Concentration (µg/ml) Absorbance at λ276nm 
1 0 0 
2 2 0.046 
3 4 0.092 
4 6 0.135 
5 8 0.185 
6 10 0.229 
 
                                Fig 19: Calibration curve of Glipizide in pH 6.8 buffer 
 
 
               It was found that the solution of Glipizide in pH 6.8 phosphate buffer show linearity 
(R
2 
= 0.999) at concentrations of 2-10 (µg/ml) and obey Beer and Lambert Law. 
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FOR IR FORMULATION 
PRECOMPRESSION STUDY 
The API and the formulated blends were evaluated for precompression parameters. 
                       Table 23: Pecompression study of API and formulated blends 
API and  
formulation 
Bulk density 
g/cm
3
 
Tapped density 
g/cm
3
 
Compressibility 
Index (%) 
Hausner’s  
Ratio 
Angle of  
Repose(Degree) 
Lisinopril 0.2947 ± 
0.0142 
0.3583 ± 
0.0209 
17.6901 ± 
0.8437 
1.2150 ± 
0.0124 
30̊ 97’ ± 
0.2654 
L-1 0.2636 ± 
0.0113 
0.3343 ± 
0.0182 
21.0989 ± 
0.9126 
1.2675 ± 
0.0146 
32̊ 04’ ± 
0.4172 
L-2 0.2783 ± 
0.0126 
0.3583 ± 
0.0209 
22.274 ± 
1.0083 
1.2868 ± 
0.0167 
30̊ 96’ ± 
1.6669 
L-3 0.2947 ± 
0.0142 
0.3846 ± 
0.0243 
23.5844 ± 
1.1246 
1.3089 ± 
0.0192 
32̊ 83’ ± 
1.5391 
Mean ± S.D (n=3) 
 
               The bulk density of the IR blends ranged from 0.2636 – 0.2947 g/cm3and the tapped 
density ranged from 0.3343 – 0.3846 g/cm3. The compressibility index of the IR blends ranged 
from 21.09% - 23.58% and Hausner’s ratio ranged from 1.2675 – 1.3089. The angle of repose of 
the IR blends ranged from 30 ̊ 96’- 32̊ 83’. The formulated blends showed good flow property, so 
wet granulation technique was used for preparing IR granules of Lisinopril. 
               The IR granules were evaluated for bulk density, tapped density, compressibility index, 
Hausner’s ratio and Angle of repose. The results are given below. 
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                           Table 24: Precompression study of formulated IR granules 
Formulation  Bulk density 
g/cm
3
 
Tapped density 
g/cm
3
 
Compressibility 
index (%) 
Hausne’s  
ratio 
Angle of 
Repose (Degree) 
L-1 0.2783 ± 
0.0126 
0.3583 ± 
0.0209 
22.27 ± 
1.0088 
1.2868 ± 
0.0167 
32̊ 61’ ± 
1.2739 
L-2 0.2783 ± 
0.0126 
0.3861 ± 
0.0243 
27.83 ± 
1.2578 
1.3862 ± 
0.0242 
31̊ 40 ± 
1.0210 
L-3 0.2947 ± 
0.0142 
0.3583 ± 
0.0209 
17.68 ± 
0.8416 
1.1687 ± 
0.0763 
31̊ 64 ± 
0.6613 
Mean ± S.D (n=3) 
 
                The bulk density of the IR granules ranged from 0.2783 – 0.2947 g/cm3and tapped 
density ranged from 0.3583 – 0.3861 g/cm3. The compressibility index of the IR granules ranged 
from 17.68% - 27.83% and Hausner’s ratio ranged from 1.1687 – 1.3862. The angle of repose of 
the IR granules ranged from 31 ̊ 40’ - 32 ̊ 61’. The formulated IR granules showed good flow 
property. 
 
FORMULATION DEVELOPMENT 
Preparation of IR tablets of Lisinopril 
              Wet granulation technique was employed for the formulation of IR granules of 
Lisinopril. Three formulations of immediate release layer of Lisinopril (L1, L2 and L3) were 
prepared using sodium starch glycolate (super disintegrant) in three different ratios. The granules 
were compressed using 10 station tablet compression machine using 10/32 punches. 
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POST COMPESSION STUDY FOR TABLETS 
UNIFORMITY OF WEEIGHT 
The uniformity of weight of the formulated tablets is given in table 25. 
                       Table 25 : Unifomity of weight of the formulated tablets 
Formulation  Uniformity of weight (mg) 
Specified limit 189.8 – 206.4 
L-1 195.34 ± 0.8935 
L-2 197.84 ± 0.5678 
L-3 198.68 ± 0.4791 
                 Mean ± S.D (n=5) 
The tablets comply with the test for uniformity of weight. 
 
TABLET THICKNESS AND DIAMETER 
The thickness and diameter of the formulated tablets is given in table 26. 
                                Table 26: Thickness and diameter of formulated tablets 
Formulation  Diameter (mm) Thickness (mm) 
Specified limit 4.5 – 5.0 2.5 – 3 
L-1 4.88 ± 0.0748 2.7 ± 0.2449 
L-2 4.84 ± 0.0489 2.84 ± 0.1019 
L-3 4.92 ± 0.0748 2.98 ± 0.04 
              Mean ± S.D (n=5) 
The tablets were found to be uniform in thickness and diameter. 
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HARDNESS 
The hardness of the formulated tablets is given in table 27. 
                                      Table 27: Hardness of formulated tablets 
Formulation  Hardness (kg/cm
2
) 
Specified limit 3.5 – 4 
L-1 3.88 ± 0.0748 
L-2 3.9 ± 0.0894 
L-3 3.96 ± 0.12 
                            Mean ± S.D (n=5) 
All the formulated tablets showed sufficient mechanical strength to resist the transportation. 
FRIABILITY 
The friability of the formulated tablets is given in table 28. 
                                     Table 28: Friability of formulated tablets 
Formulation  % Friability  
Specified limit Not more than 1.0% 
L-1 0.6277 ± 0.0912 
L-2 0.3347 ± 0.0392 
L-3 0.7076 ± 0.0712 
                             Mean ± S.D (n=3) 
 
              The percentage friability of all the formulations was within the acceptable limits. i.e not 
more than 1%. 
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DRUG CONTENT 
The drug content of the IR tablets is given in table 29. 
                                Table 29: Drug content of formulated IR tablets 
Formulation  (% w/w) Drug Content 
Specified limit 90 – 110% 
L-1 95.89 ± 0.9093 
L-2 97.59 ± 0.4994 
L-3 99.09 ± 0.4532 
                     Mean ± S.D (n=3) 
 
                                         Fig 20: Drug content of IR tablets 
  
 
              The drug contents of all three IR formulations were found to be within the limit. i.e the 
drug content was not less than 90% and not more than 110% (as per IP: 2010). 
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DISINTEGRATION TIME 
The disintegration time of the IR tablets is given in table 30. 
                                      Table 30: Disintegration time of IR tablets 
Formulation  Disintegration time (seconds) 
L-1 43.02 ± 0.8369 
L-2 27.05 ± 0.8090 
L-3 19.07 ± 0.8492 
                     Mean ± S.D (n=3) 
 
                                         Fig 21: Disintegration time of IR tablets 
 
 
                 The disintegration time of the IR tablets ranged from 43.02 seconds to 19.07seconds. 
The disintegration time of the IR tablets containing 8% sodium starch glycolate was found to 
have optimum disintegration time (19.07seconds) for IR tablets. 
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IN VITRO DISSOLUTION STUDY 
The in vitro dissolution of immediate release formulations of Lisinopril is shown in table 31 and 
Fig 22. 
           Table 31: In vitro dissolution study of Immediate release tablets  
 
Time(minutes) 
                               Cumulative % Drug release 
      L-1 L-2 L-3 
0 0 ± 0.0000 0 ± 0.0000 0 ± 0.0000 
10 62.6 ± 0.7761 79.42 ± 0.5316 86.58 ± 0.7331 
20 71.43 ± 0.8859 86.43 ± 0.5461 93.49 ± 0.5218 
30 79.26 ± 0.7318 92.63 ± 0.8941 98.74 ± 0.5925 
40 86.14 ± 0.8942 98.87 ± 0.5041  
50 93.54 ± 0.9474   
60 98.66 ± 0.5470   
Mean ± S.D (n=3) 
               The in vitro dissolution study of IR tablets showed that 8% concentration of SSG was 
found to be optimum for immediate release of Lisinopril. The 4% and 6% concentration of SSG 
was found to be releasing the drug slowly when compared to 8% SSG. The 8% concentration of 
SSG released 98.94% at the end of 30minutes. Therefore formulation L-3 was optimized and 
selected for final bilayer tablets. 
                           Fig 22: In vitro dissolution study of IR tablets of Lisinopril 
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               The in vitro dissolution study of IR tablets showed that 8% concentration of SSG was 
found to be optimum for immediate release of Lisinopril. The 4% and 6% concentrationof SSG 
was found to be releasing the drug slowly when compared to 8% SSG. The 8% concentration of 
SSG released 98.74% at the end of 30 minutes. Therefore formulation L-3 was optimized and 
selected for final bilayer tablets. 
FOR SR TABLETS 
PRECOMPRESSION STUDY 
             The API and the formulated blends of SR were evaluated for precompression 
parameters. The results are given in table 32. 
                         Tablet 32: Precompresson study of API and formulated blends 
API and  
formulation 
Bulk density 
g/cm
3
 
Tapped  
Density g/cm
3
 
Compressibility 
Index (%) 
Hausner’s  
ratio 
Angle of 
Repose(Degree) 
Glipizide 0.2636 ± 
0.0113 
0.3572 ± 
0.0222 
26.36 ± 
1.1435 
1.3540 ± 
0.02658 
28̊ 66’ ± 
0.9203 
G-1 0.2503 ±  
0.0102 
0.3343 ± 
0.01822 
25.05 ± 
1.0133 
1.3344 ± 
0.0180 
31̊ 34’ ± 
0.3390 
G-2 0.2503 ± 
0.0102 
0.2947 ± 
0.0142 
15.02 ± 
0.6169 
1.1769 ± 
0.0085 
31̊ 40 ± 
1.0210 
G-3 0.2636 ± 
0.0113 
0.3133 ± 
0.0160 
15.82 ± 
0.6901 
1.1881 ± 
0.0097 
32̊ 58 ± 
1.2364 
G-4 0.2783 ± 
0.0126 
0.3343 ± 
0.0182 
16.70 ± 
0.7514 
1.2007 ± 
0.0108 
31̊ 40 ± 
0.9566 
G-5 0.2636 ± 
0.0113 
0.2947 ± 
0.0160 
15.82 ± 
0.6899 
1.1179 ± 
0.0059 
32̊ 83 ± 
0.2864 
Mean ± S.D (n=3) 
                  The bulk density of the SR blends ranged from 0.2503 – 0.2783 g/cm3and the tapped 
density ranged from o.2947 -0.3572 g/cm
3. 
The compressibility index ranged from 15.82 – 
26.36% and Hausner’s ratio ranged from 1.1179 – 1.3540.  
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                 The angle of repose of the SR blend ranged from 28 ̊ 66’ - 32̊ 83. The formulated 
blends showed good flow property so wet granulation technique was used for preparing SR 
granules of Glipizide. The SR granules were evaluated for bulk density, tapped density, 
compressibility index, Hausner’s ratio and angle of repose. The results are given in table 33. 
                    Table 33: Precompression study of sustained release granules 
Formulation  Bulk density 
g/cm
3
 
Tapped density 
g/cm
3
 
Compressibility 
Index (%) 
Hausner’s 
ratio 
Angle of  
Repose 
G-1 0.2783 ± 
0.0126 
0.3583 ± 
0.0209 
22.27 ± 
1.0088 
1.2868 ± 
0.0167 
31̊ 34 ± 
0.3390 
G-2 0.3133 ± 
0.0160 
0.3861 ± 
0.0243 
18.79 ± 
0.9600 
1.2316 ± 
0.0145 
31̊ 25 ± 
0.8739 
G-3 0.2503 ± 
0.0102 
0.2947 ± 
0.0142 
15.02 ± 
0.6169 
1.1769 ± 
0.0085 
31̊ 88’ ± 
0.3253 
G-4 0.2636 ± 
0.0113 
0.3133 ± 
0.0160 
15.82 ± 
0.6901 
1.1881 ± 
0.0097 
31̊ 17 ± 
0.6636 
G-5 0.2783 ± 
0.0126 
0.3343 ± 
0.0182 
16.70 ± 
0.7514 
1.2007 ± 
0.0108 
31̊ 73’ ± 
0.4286 
Mean ± S.D (n=3) 
                The bulk density of the SR granules ranged from 0.2503 – 0.2783 g/cm3and the tapped 
density ranged from 0.2947 -0.3583 g/cm
3
. the compressibility index ranged from 15.02 – 
22.27% and Hausner’s ratio ranged from 1.1769 – 1.2868. The angle of repose of the SR 
granules ranged from 31̊ 17’ - 31 ̊ 88’. The formulated SR granules showed good flow property.  
FORMULATION DEVELOPMENT 
                Wet granulation technique was employed for the formulation of SR granules of 
Glipizide. Five batches of SR granules were prepared by using hydrophilic polymer HPMC 
K100M and hydrophobic polymer EC in varying proportions. The formulations were 
compressed on a 10station tablet compression machine. 
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POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT 
The uniformity of weight of the formulated tablets is given in table 34. 
                       Table 34: Uniformity of weight of the formulated tablets 
Formulation  Uniformity of weight (mg) 
Specified limit 240-270 
G-1 251.32 ± 0.9579 
G-2 261.38 ± 0.8653 
G-3 254.38 ± 0.5715 
G-4 254.00 ± 0.8993 
G-5 254.4 ± 0.9392 
                   Mean ± S.D (n=5) 
The tablet complies with the test for uniformity of weight. 
TABLET THICKNESS, DIAMETER AND HARDNESS 
The thickness, diameter and hardness of the formulated tablets are given in table 35. 
                 Table 35: Thickness, Diameter and Hardness of formulated tablets 
Formulation  Thickness (mm) Diameter (mm) Hardness(Kg/cm
2
) 
Specified limit 2.5 – 3.5 4.5 – 5.5 4-6 
G-1 2.88 ± 0.3187 4.8 ± 0.2449 4.92 ± 0.1469 
G-2 2.82 ± 0.1939 4.82 ± 0.1469 5.06 ± 0.1356 
G-3 2.88 ± 0.0748 4.86 ± 0.1019 5.2 ± 0.1095 
G-4 3.08 ± 0.1720 4.94 ± 0.1356 5.24 ± 0.0489 
G-5 3.02 ± 0.1166 4.8 ± 0.1095 5 ± 0.0894 
Mean ± S.D (n=5) 
The tablets were found to be uniform in thickness, diameter and hardness. 
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FRIABILITY 
The friability of formulated tablet is given in table 36. 
                                   Table 36: Friability of formulated tablets 
Formulation  Friability  
Specified limit Not more than 1.0% 
G-1 0.7923 ± 0.0526 
G-2 0.8273 ± 0.0600 
G-3 0.7019 ± 0.0646 
G-4 0.9153 ± 0.0527 
G-5 0.6517 ± 0.0498 
                   Mean ± S.D (n=3)                
           The percentage friability of all formulations were within the acceptable limits. i.e. not less 
than 1%. 
DRUG CONTENT 
The percentage drug content values of the SR tablets are given in table table 37 and Fig 23. 
                      Table 37: Drug content (%w/w) of formulated SR tablets 
Formulation  Drug content (%w/w)  
Specified limit  90-110% 
G-1 96.22 ± 0.8538 
G-2 98.47 ± 0.6375 
G-3 97.52 ± 0.9785 
G-4 98.95 ± 0.2174 
G-5 99.30 ± 0.2833 
                   Mean ± S.D (n=3) 
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                                     Fig 23: Percentage drug content of SR tablets 
 
 
               The drug contents of all five SR formulations were found to be within the limit. i.e the 
drug content was not less than 90% and not more than 110% (as per IP: 2010) 
 
IN VITRO DISSOLUTION STUDY OF SR TABLETS 
The in vitro dissolution study of SR tablets is given in table 38 and Fig 24. 
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                          Table 38: In vitro dissolution study of SR tablets 
Time  
(minutes) 
G-1 G-2 G-3 G-4 G-5 
0 0 ± 0.0000 0 ± 0.0000 0 ± 0.0000 0 ± 0.0000 0 ± 0.0000 
30 42.38 ± 
0.5646 
42.47 ± 
0.7855 
35.34 ± 
0.8794 
25.42 ± 
0.7870 
21.97 ±  
0.5142 
60 49.55 ± 
0.4883 
45.57 ± 
0.5358 
40.50 ± 
0.8211 
31.59 ± 
0.7200 
26.37 ±  
0.8169 
120 57.22 ± 
0.8032 
54.56 ± 
0.8515 
47.28 ± 
0.9883 
37.44 ± 
0.7268 
32.59 ±  
0.7453 
180 66.05 ± 
0.6513 
64.53 ± 
0.6033 
53.28 ± 
0.8118 
43.36 ± 
0.9340 
39.45 ±  
0.8172 
240 72.56 ± 
0.6287 
70.50 ± 
0.6697 
60.38 ± 
0.7189 
49.45 ± 
0.5832 
46.84 ±  
0.9150 
300 82.24 ± 
0.6975 
78.31 ± 
0.7524 
69.37 ± 
0.7451 
55.28 ± 
0.8374 
53.10 ± 
1.3540 
360 90.25 ± 
0.7721 
83.58 ± 
0.5930 
76.45 ± 
0.9353 
61.45 ± 
0.7162 
58.57 ±  
0.9360 
420 97.39 ± 
0.9471 
89.64 ± 
0.8051 
82.28 ± 
0.7587 
68.25 ± 
0.9554 
65.53 ±  
1.3214 
480 99.42 ± 
0.3890 
96.49 ± 
0.9182 
87.78 ± 
0.8722 
72.28 ± 
0.9393 
69.40 ±  
0.7156 
540  99.31 ± 
0.2246 
92.35 ± 
0.9594 
78.26 ± 
0.8334 
76.54 ± 
0.8234 
600   98.23 ± 
0.4325 
86.92 ± 
0.8123 
83.78 ± 
0.7659 
660    97.73 ± 
0.7683 
90.34 ± 
0.6785 
720     99.82 ±  
0.6895 
Mean ± S.D (n=3) 
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                                   Fig 24: In vitro dissolution study of S tablets 
 
The results of In vitro dissolution study of SR tablets showed that 
 The formulation G1 containing EC(20%) had released the drug 99.42% in 8 hours. 
 The formulation G2 containing HPMC K100M (20%) had released the drug 99.31% in 9 
hours. 
 The formulation G3 containing EC and HPMC K100M (1:1) had released the drug 
98.23% in 10 hours. The release of the drug was retarded when compared to the 
formulation G2. 
 The formulation G4 containing EC and HPMC K100 M (1:2). The release of the drug 
(97.73% in 11 hrs) was retarded when compared to G3. 
 The formulation G5 containing EC and HPMC K100M (1:4). The release of the drug 
(99.82% in 12 hrs) was retarded when compared to formulation G4. 
 Based on the comparative release profile, formulation G5 was selected for the final 
bilayer tablets. 
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FORMULATION DEVELOPMENT 
PREPARATION OF BILAYER TABLETS 
1. Optimized immediate layer of Lisinopril was prepared by wet granulation method. 
2. Optimized sustained release layer of Glipizide was prepared by wet granulation method. 
The granules were compressed on 10 station bilayer tablet compression machine.  
POST COMPRESSION STUDY OF BILAYER TABLETS 
                      Table 39: Post compression study of Bilayer tablets 
Parameters  Bilayer tablet 
Uniformity of weight (mg) 448.18 ± 0.8863 
Thickness (mm) 5.88 ± 0.0748 
Diameter (mm) 4.91 ± 0.1065 
Hardness (kg/cm
2
) 5.82 ± 0.1648 
Friability (%) 0.3692 ± 0.0613 
Drug content* 
(simultaneous estimation method) 
1. Lisinopril 
2. Glipizide 
 
 
1. 98.26 ± 0.5157 
2. 93.32 ± 0.8906 
            Mean ± S.D (n=5)           *Mean ± S.D (n=3 
IN VITRO DISSOLUTION STUDY OF LISINOPRIL IN BILAYER TABLET 
The in vitro dissolution study of drugs in bilayer tablets is given in table 40, 41 and Fig 25, 26. 
            Table 40: The in vitro dissolution study of Lisinopril in bilayer tablet 
Time (minutes) % Drug release 
0 0 ± 0.0000 
10 79.27 ± 0.2236 
20 90.15 ± 0.1342 
30 98.74 ± 0.1855 
            Mean ± S.D (n=3) 
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                     Fig 25:The in vitro dissolution study of Lisinopril in bilayer tablet 
 
TABLE 41: IN VITRO DISSOLUTION STUDY OF GLIPIZIDE IN BILAYER TABLET 
Time (minutes) % Drug release 
0 0 ± 0.0000 
30 20.87 ± 0.1885 
60 26.79 ± 0.3091 
120 32.43 ± 0.1114 
180 39.66 ± 0.2315 
240 47.05 ± 0.1586 
300 53.79 ± 0.4348 
360 59.95 ± 0.3069 
420 65.88 ± 0.5307 
480 71.76 ± 0.3943 
540 77.54 ± 0.4231 
600 83.78 ± 0.3465 
660 90.97 ± 0.2341 
720 99.54 ± 0.1994 
                   Mean ± S.D (n=3) 
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Fig 26: In vitro dissolution study of Glipizide in bilayer tablet 
 
 
IN VITRO RELEASE KINETICS 
                In order to describe the release kinetics the values obtained from in vitro dissolution of 
Glipizide from bilayer tablets were fitted in various kinetic dissolution models like zero order, 
first order, Higuchi, Korsmeyer Peppas and Hixson Crowell respectively. The various 
parameters like the time exponent (n), the release rate constant (k) and the regression co-efficient 
(R
2
) were also calculated. In a set of data, the model showing the highest value of R
2
was taken as 
the best fit model. The results are given in table 42. 
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                                        Table 41: In vitro release kinetics of bilayer tablets 
Time 
(hours) 
%Cum drug 
release 
%Cum drug 
Remaining 
(g) 
Log % 
Cum 
Drug 
Remaining 
(g) 
Square 
Root of 
time 
Log 
time 
Log % 
Cum drug 
release 
Cube root 
Of %drug 
Remaining 
(g) 
0 0 100 2 0 -∞ -∞ 4.6415 
0.5 20.87 79.13 1.8983 0.7071 0.3010 1.3195 4.293 
1 26.79 73.21 1.8645 1.0 0.0 1.4279 4.1833 
2 32.42 67.58 1.8298 1.4142 0.3010 1.5108 4.0732 
3 39.66 60.34 1.7806 1.7320 0.4771 1.5983 3.9222 
4 47.05 52.95 1.7238 2.0 0.6020 1.6725 3.7551 
5 53.79 46.21 1.6647 2.2360 0.6989 1.7307 3.5884 
6 59.95 40.05 1.6026 2.4494 0.7781 1.7777 3.4213 
7 65.88 34.12 1.5330 2.6457 0.8450 1.8187 3.2434 
8 71.76 28.24 1.4508 2.8284 0.9030 1.8558 3.0452 
9 77.54 22.46 1.3514 3.0 0.9542 1.8895 2.8214 
10 83.78 16.22 1.2100 3.1622 1.0 1.9231 2.5313 
11 90.97 9.03 0.9556 3.3166 1.0413 1.9588 2.0823 
12 99.54 0.46 0.3372 3.4641 1.0791 1.9979 0.7719 
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                                         Fig 27: Zero order release kinetics 
 
                                                  Fig 28: First order release kinetics 
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                                              Fig 29: Higuchi diffusion kinetics 
 
 
 
                                            Fig 30: Korsmeyer Peppas equation 
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                                        Fig 31: Hixson Crowell cube root equation 
 
 
Table 42 :Data of various parameters of model fitting for Glipizide release from the 
optimized bilayer formulation 
Formulation  Zero order First order Higuchi Korsmeyer 
Peppas 
Hixson Crowell 
Optimised 
formulation 
R
2
 R
2
 R
2
 R
2
 n R
2
 
0.970 0.974 0.988 0.915 0.605 0.983 
 
Determination of drug release mechanism of optimised bilayer tablets 
 The order of release was found to be first order, in which R2value was closer to 1 than the 
value of R
2
of the first order equation. 
 In Higuchi diffusion kinetics the R2value was near to 1. So it was concluded that the 
optimized formulation follows Higuchi diffusion mechanism. 
 The n value of Korsmeyer Peppas equation was found to be 0.605, from that it was 
concluded that the release followed nonfickian transport. 
y = -0.178x + 4.465
R² = 0.983
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 2 4 6 8 10
C
u
b
e
 r
o
o
t 
o
f 
cu
m
 %
 d
ru
g 
re
m
ai
n
in
g
Time (Hours)
Hixson crowell cube root equation
10. Results and Discussion 
 
Department of Pharmaceutics, Madras Medical College Page 115 
 
 Swelling hydration of the polymer matrix, dissolution of the drug in the polymer matrix, 
and diffusion of the drug through the polymer matrix and surface erosion of the matrix 
also plays role in the drug release. The results showed that the formulation followed first 
order release. 
STABILITY STUDIES 
The optimised bilayer tablets were subjected to stability studies and the results are given in table 
43 and 44. 
       Table 43: Stability study of physical parameters of the optimized bilayer tablets 
Parameters  Initial  1
st
 month 2
nd
 month 3
rd
 month 
Uniformity of weight 448.18 ±  
0.8863 
448.79 ±  
0.4443 
448.92 ±  
0.4608 
448.94 ±  
0.4108 
Thickness (mm) 5.88 ±  
0.0748 
5.88 ±  
0.0748 
5.88 ±  
0.0748 
5.88 ±  
0.0748 
Diameter (mm) 4.91 ±  
0.1065 
4.91 ±  
0.1065 
4.91 ±  
0.1065 
4.91 ±  
0.1065 
Hardness (kg/cm
2
) 5.82 ±  
0.1648 
5.82 ±  
0.1648 
5.82 ±  
0.1648 
5.82 ±  
0.1648 
Friability (%) 0.3692 ±  
0.0613 
0.2948 ± 
0.0038 
0.3172 ± 
0.0033 
0.3220 ± 
0.0017 
 
                          Table 44: Assay and dissolution profile of bilayer tablet 
Time interval 
(month) 
Drug content (% w/w) Cumulative % drug release 
Lisinopril Glipizide Lisinopril  
(at the end of of 
30mins)  
Glipizide 
(at the end of 
12hours)  
Initial  98.26 ± 0.5157 93.32 ± 0.8906 98.74 ± 0.1855 99.54 ± 0.1994 
1
st
 month 98.84 ± 0.3024 93.87 ± 0.1835 98.81 ± 0.2245 99.21 ± 0.2290 
2
nd
 month 98.77 ± 0.3597 93.96 ± 0.2145 98.65 ± 0.3365 99.27 ± 0.3351 
3
rd
 month 98.91 ± 0.3512 94.02 ± 0.2160 98.71 ± 0.3447 99.17 ± 0.3108 
 
      
    
Summary & 
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                                            11. SUMMARY AND CONCLUSION 
SUMMARY 
              The present work involves the formulation development, optimization and In-vitro 
evaluation of bilayer tablet containing Lisinopril in the immediate release layer and Glipizide in 
the sustained release layer, using sodium starch glycolate as a super disintegrant for the 
immediate release layer and the hydrophilic matrix HPMC K100M, hydrophobic matrix Ethyl 
cellulose are used in the sustained release layer.  
              Bilayer tablet showed as initial burst effect to provide dose of immediate release layer 
Lisinopril to control the blood pressure level and the sustained release of Glipizide for 24hours to 
control the blood glucose level. The developed formulation shows an alternative to the 
conventional dosage form for the treatment of diabetes along with diabetic hypertension and 
nephropathy. 
 
 Under the preformulation studies, API (Active Pharmaceutical Ingredient) 
characterization and drug-excipient compatibility studies were carried out. The API 
characterization showed compliance with the drug characteristics. 
 
 The polymers and other excipients were selected based on the satisfying results produced 
during drug-excipient compatibility studies to develop the final formulation. 
 
 
 Immediate and sustained release tablets were formulated by wet granulation method 
because of the poor flow property of the blends. 
 
 The formulated granules were evaluated for precompression studies which showed that 
the flow property was good. 
 
 
 The formulated tablets were found to be within the limits with respect to uniformity of 
weight, hardness, thickness, diameter and friability. 
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 The disintegration time of IR tablets containing SSG 8% was found to be optimum. 
 
 The drug content of the formulated IR and SR tablets were found to be within limits. 
 
 
 Based on the in vitro dissolution studies of IR tablets, formulation L3 was optimised and 
selected for final bilayer tablets. 
 
 Based on the in vitro dissolution studies of SR tablets, formulation G5 containing EC and 
HPMC K100M (1:4). It released the drug 99.82% in 24hours. This formulation G5 was 
optimised and selected for bilayer tablets. 
 
 
 The optimised IR and SR formulations were compressed into bilayer tablets. 
 
 The formulated bilayer tablets were found to be within the limits with respect to 
uniformity of weight, hardness, thickness, diameter and friability. 
 
 
 The drug content of the bilayer tablets were estimated by simultaneous estimation 
method and it was found to be within the pharmacopoeial limit. 
 
 The in vitro dissolution studies of optimised bilayer tablets were released the drug upto 
24 hours. 
 
 
 The release kinetics of the optimized tablets showed that it follows zero order release 
kinetics. The release of the drug from the dosage form was found to be by dissolution and 
non fickian release. 
 
 Stability studies of optimized bilayer tablets were carried out according to ICH guidlines. 
It indicated that the bilayer tablets are stable and does not show any significant changes 
in the physical characteristics, drug content and dissolution. The results obtained were 
found to be within the limits. 
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CONCLUSION 
 Success of the in vitro drug release studies recommends the product for the further 
invivo studies, which may improve patient compliance. 
 From the literature, it is seen that Lisinopril as an individual dosage form is used in 
the management of hypertension in patients with type I and type II diabetes mellitus. 
Glipizide is given as alone or in combination with other antidiabetic drugs in patients 
with type II diabetes. 
 Lisinopril potentiate the effect of Glipizide. Hence the bilayer tablets of Lisinopril 
and Glipizide were used to improve patient compliance towards the effective 
management diabetes along with diabetic hypertension and nephropathy. 
 Combination of Lisinopril as an immediate release layer and Glipizide as a sustained 
release layer reduces polytherapy to monotherapy. 
 From the results, formulated bilayer tablet provides better in vitro release from 
immediate release layer as well as sustained release layer. 
 The data obtained from in vitro release study for sustained release layer were fitted to 
various mathematical model like zero order, first order, Higuchi model and Peppas 
model. The results of mathematical model fitting of data obtained indicated that, the 
best fit model was zero order. Thus the release of the drug from the dosage form was 
found to be by dissolution and non fickian release. 
 The stability studies indicated that the bilayer tablets are stable and does not show 
any significant changes. 
 
FUTURE PLAN 
 Scale up studies of the optimized formulation. 
 In vivo studies and in vivo- in vitro correlation studies. 
 Bioequivalence studies with the marketed formulations. 
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